<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Comprehensive Drug Reference Guide</title>
    <style>
        * { box-sizing: border-box; }
        
        :root {
            --primary: #2563eb;
            --primary-dark: #1d4ed8;
            --secondary: #059669;
            --warning: #d97706;
            --danger: #dc2626;
            --purple: #7c3aed;
            --bg-light: #f8fafc;
            --border: #e2e8f0;
            --text: #1e293b;
            --text-muted: #64748b;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
            font-size: 10pt;
            line-height: 1.5;
            margin: 0;
            padding: 0;
            color: var(--text);
            background: var(--bg-light);
        }
        
        /* Header */
        .main-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--purple) 100%);
            color: white;
            padding: 25px 30px;
            position: sticky;
            top: 0;
            z-index: 1000;
            box-shadow: 0 2px 10px rgba(0,0,0,0.15);
        }
        
        .main-header h1 {
            margin: 0;
            font-size: 22pt;
            font-weight: 700;
        }
        
        .main-header .subtitle {
            margin: 5px 0 0 0;
            opacity: 0.9;
            font-size: 11pt;
        }
        
        .header-stats {
            display: flex;
            gap: 20px;
            margin-top: 12px;
            flex-wrap: wrap;
        }
        
        .stat-badge {
            background: rgba(255,255,255,0.2);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 10pt;
        }
        
        /* Search */
        .search-container {
            background: white;
            padding: 15px 30px;
            border-bottom: 1px solid var(--border);
            position: sticky;
            top: 95px;
            z-index: 999;
        }
        
        .search-wrapper {
            max-width: 600px;
            position: relative;
        }
        
        .search-input {
            width: 100%;
            padding: 12px 45px 12px 15px;
            border: 2px solid var(--border);
            border-radius: 10px;
            font-size: 14px;
            background: var(--bg-light);
            -webkit-appearance: none;
        }
        
        .search-input:focus {
            outline: none;
            border-color: var(--primary);
            box-shadow: 0 0 0 3px rgba(37, 99, 235, 0.1);
        }
        
        .search-clear {
            position: absolute;
            right: 12px;
            top: 50%;
            transform: translateY(-50%);
            background: var(--border);
            border: none;
            width: 24px;
            height: 24px;
            border-radius: 50%;
            cursor: pointer;
            display: none;
            align-items: center;
            justify-content: center;
            font-size: 12px;
        }
        
        .search-results-count {
            margin-top: 8px;
            font-size: 12px;
            color: var(--text-muted);
        }
        
        /* Container */
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 20px;
        }
        
        /* Navigation */
        .nav-section {
            background: white;
            border-radius: 12px;
            padding: 20px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
        }
        
        .nav-title {
            font-size: 14pt;
            font-weight: 700;
            color: var(--primary);
            margin: 0 0 15px 0;
            border-bottom: 2px solid var(--primary);
            padding-bottom: 8px;
        }
        
        .category-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 10px;
        }
        
        .category-link {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 10px 12px;
            background: var(--bg-light);
            border: 1px solid var(--border);
            border-radius: 8px;
            text-decoration: none;
            color: var(--text);
            transition: all 0.2s;
        }
        
        .category-link:hover {
            background: var(--primary);
            color: white;
            border-color: var(--primary);
        }
        
        .category-icon {
            font-size: 16px;
        }
        
        .category-name {
            font-weight: 600;
            font-size: 11pt;
        }
        
        .category-count {
            margin-left: auto;
            background: white;
            padding: 2px 8px;
            border-radius: 10px;
            font-size: 10px;
            font-weight: 600;
            color: var(--text-muted);
        }
        
        /* Drug Category Sections */
        .drug-category {
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
            overflow: hidden;
        }
        
        .category-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 15px 20px;
            cursor: pointer;
            display: flex;
            align-items: center;
            justify-content: space-between;
        }
        
        .category-header h2 {
            margin: 0;
            font-size: 14pt;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        
        .category-header .toggle {
            font-size: 16px;
            transition: transform 0.3s;
        }
        
        .category-header.collapsed .toggle {
            transform: rotate(-90deg);
        }
        
        .category-content {
            padding: 15px 20px;
        }
        
        .category-content.collapsed {
            display: none;
        }
        
        /* Drug Cards */
        .drug-card {
            border: 1px solid var(--border);
            border-radius: 10px;
            margin-bottom: 15px;
            overflow: hidden;
            transition: box-shadow 0.2s;
        }
        
        .drug-card:hover {
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }
        
        .drug-card.hidden {
            display: none;
        }
        
        .drug-header {
            background: var(--bg-light);
            padding: 12px 15px;
            border-bottom: 1px solid var(--border);
            cursor: pointer;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        
        .drug-name {
            font-weight: 700;
            font-size: 12pt;
            color: var(--primary-dark);
        }
        
        .drug-brand {
            font-size: 10pt;
            color: var(--text-muted);
            font-style: italic;
        }
        
        .drug-class-badge {
            margin-left: auto;
            background: var(--primary);
            color: white;
            padding: 3px 10px;
            border-radius: 15px;
            font-size: 9pt;
            font-weight: 600;
        }
        
        .drug-toggle {
            color: var(--text-muted);
            font-size: 14px;
        }
        
        .drug-body {
            padding: 15px;
            display: none;
        }
        
        .drug-body.expanded {
            display: block;
        }
        
        .drug-section {
            margin-bottom: 12px;
        }
        
        .drug-section:last-child {
            margin-bottom: 0;
        }
        
        .drug-section-title {
            font-weight: 700;
            font-size: 10pt;
            color: var(--secondary);
            margin-bottom: 4px;
            display: flex;
            align-items: center;
            gap: 6px;
        }
        
        .drug-section-content {
            font-size: 10pt;
            color: var(--text);
        }
        
        .drug-section-content ul {
            margin: 4px 0;
            padding-left: 18px;
        }
        
        .drug-section-content li {
            margin: 3px 0;
        }
        
        /* Special boxes */
        .warning-box {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .warning-box::before {
            content: "‚ö†Ô∏è ";
        }
        
        .black-box {
            background: #1f2937;
            color: white;
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .black-box::before {
            content: "‚ò†Ô∏è BLACK BOX: ";
            font-weight: bold;
        }
        
        .pearl-box {
            background: #dbeafe;
            border: 1px solid var(--primary);
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .pearl-box::before {
            content: "üíé ";
        }
        
        /* Cross-links */
        .cross-links {
            margin-top: 10px;
            padding-top: 10px;
            border-top: 1px dashed var(--border);
        }
        
        .cross-links-title {
            font-size: 9pt;
            color: var(--text-muted);
            margin-bottom: 5px;
        }
        
        .guide-link {
            display: inline-block;
            background: var(--bg-light);
            border: 1px solid var(--border);
            padding: 3px 8px;
            border-radius: 4px;
            font-size: 9pt;
            text-decoration: none;
            color: var(--primary);
            margin-right: 5px;
            margin-bottom: 5px;
        }
        
        .guide-link:hover {
            background: var(--primary);
            color: white;
        }
        
        /* Dosing table */
        .dosing-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 9.5pt;
            margin: 8px 0;
        }
        
        .dosing-table th, .dosing-table td {
            border: 1px solid var(--border);
            padding: 6px 10px;
            text-align: left;
        }
        
        .dosing-table th {
            background: var(--bg-light);
            font-weight: 600;
        }
        
        /* Footer */
        .footer {
            background: #1e293b;
            color: white;
            padding: 30px;
            text-align: center;
            margin-top: 30px;
        }
        
        .footer p {
            margin: 5px 0;
            opacity: 0.8;
            font-size: 10pt;
        }
        
        .back-to-top {
            display: inline-block;
            background: var(--primary);
            color: white;
            padding: 8px 16px;
            border-radius: 6px;
            text-decoration: none;
            font-size: 10pt;
            margin-top: 10px;
        }
        
        /* Responsive */
        @media (max-width: 768px) {
            .category-grid {
                grid-template-columns: 1fr;
            }
            
            .main-header h1 {
                font-size: 18pt;
            }
            
            .search-container {
                top: 85px;
            }
        }
        
        /* Print */
        @media print {
            .main-header, .search-container, .nav-section {
                display: none;
            }
            
            .drug-body {
                display: block !important;
            }
            
            .drug-card {
                page-break-inside: avoid;
            }
        }
        
        /* Category-specific colors */
        .cat-antibiotics { --cat-color: #dc2626; }
        .cat-cardiac { --cat-color: #e11d48; }
        .cat-anticoag { --cat-color: #9333ea; }
        .cat-neuro { --cat-color: #2563eb; }
        .cat-pulm { --cat-color: #0891b2; }
        .cat-gi { --cat-color: #059669; }
        .cat-endo { --cat-color: #ca8a04; }
        .cat-rheum { --cat-color: #7c3aed; }
        .cat-renal { --cat-color: #0d9488; }
        .cat-tox { --cat-color: #dc2626; }
        .cat-pain { --cat-color: #ea580c; }
        .cat-psych { --cat-color: #6366f1; }
        .cat-other { --cat-color: #64748b; }
    </style>
</head>
<body>

<div class="main-header">
    <h1>üíä Comprehensive Drug Reference Guide</h1>
    <p class="subtitle">Clinical Pharmacology for Hospital Medicine ‚Ä¢ Cross-linked to IMCRG, Nephrology, Rheumatology & ID Guides</p>
    <div class="header-stats">
        <span class="stat-badge">üìä 500+ Medications</span>
        <span class="stat-badge">üìÅ 45 Categories</span>
        <span class="stat-badge">üîó Cross-Referenced</span>
        <span class="stat-badge">üì± iPad Optimized</span>
    </div>
</div>

<div class="search-container">
    <div class="search-wrapper">
        <input type="text" class="search-input" id="drugSearch" placeholder="Search by drug name, class, or indication..." autocomplete="off" autocorrect="off" autocapitalize="off" spellcheck="false">
        <button class="search-clear" id="searchClear" type="button">‚úï</button>
    </div>
    <div class="search-results-count" id="searchResults"></div>
</div>

<div class="container">

<!-- NAVIGATION -->
<div class="nav-section" id="toc">
    <h2 class="nav-title">üìö Quick Navigation by Category</h2>
    <div class="category-grid">
        <a href="#antibiotics-penicillins" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Penicillins</span>
            <span class="category-count">12</span>
        </a>
        <a href="#antibiotics-cephalosporins" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Cephalosporins</span>
            <span class="category-count">12</span>
        </a>
        <a href="#antibiotics-carbapenems" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Carbapenems</span>
            <span class="category-count">4</span>
        </a>
        <a href="#antibiotics-fluoroquinolones" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Fluoroquinolones</span>
            <span class="category-count">5</span>
        </a>
        <a href="#antibiotics-aminoglycosides" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Aminoglycosides</span>
            <span class="category-count">5</span>
        </a>
        <a href="#antibiotics-macrolides" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Macrolides</span>
            <span class="category-count">4</span>
        </a>
        <a href="#antibiotics-glycopeptides" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Glycopeptides</span>
            <span class="category-count">4</span>
        </a>
        <a href="#antibiotics-other" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Other Antibiotics</span>
            <span class="category-count">18</span>
        </a>
        <a href="#antifungals" class="category-link">
            <span class="category-icon">üçÑ</span>
            <span class="category-name">Antifungals</span>
            <span class="category-count">14</span>
        </a>
        <a href="#antivirals" class="category-link">
            <span class="category-icon">ü¶†</span>
            <span class="category-name">Antivirals</span>
            <span class="category-count">22</span>
        </a>
        <a href="#anticoagulants" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Anticoagulants</span>
            <span class="category-count">10</span>
        </a>
        <a href="#antiplatelets" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Antiplatelets</span>
            <span class="category-count">6</span>
        </a>
        <a href="#thrombolytics" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Thrombolytics</span>
            <span class="category-count">4</span>
        </a>
        <a href="#reversal-agents" class="category-link">
            <span class="category-icon">‚Ü©Ô∏è</span>
            <span class="category-name">Reversal Agents</span>
            <span class="category-count">11</span>
        </a>
        <a href="#cardiac-antihypertensives" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Antihypertensives</span>
            <span class="category-count">32</span>
        </a>
        <a href="#cardiac-antiarrhythmics" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Antiarrhythmics</span>
            <span class="category-count">11</span>
        </a>
        <a href="#cardiac-vasopressors" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Vasopressors/Inotropes</span>
            <span class="category-count">7</span>
        </a>
        <a href="#cardiac-lipids" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Lipid Agents</span>
            <span class="category-count">4</span>
        </a>
        <a href="#cardiac-hf" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Heart Failure</span>
            <span class="category-count">4</span>
        </a>
        <a href="#diabetes" class="category-link">
            <span class="category-icon">ü©∫</span>
            <span class="category-name">Diabetes Medications</span>
            <span class="category-count">10</span>
        </a>
        <a href="#corticosteroids" class="category-link">
            <span class="category-icon">üíâ</span>
            <span class="category-name">Corticosteroids</span>
            <span class="category-count">7</span>
        </a>
        <a href="#immunosuppressants" class="category-link">
            <span class="category-icon">üõ°Ô∏è</span>
            <span class="category-name">Immunosuppressants</span>
            <span class="category-count">10</span>
        </a>
        <a href="#dmards-biologics" class="category-link">
            <span class="category-icon">üõ°Ô∏è</span>
            <span class="category-name">DMARDs/Biologics</span>
            <span class="category-count">25</span>
        </a>
        <a href="#gi-hepatic" class="category-link">
            <span class="category-icon">ü´Å</span>
            <span class="category-name">GI/Hepatic</span>
            <span class="category-count">25</span>
        </a>
        <a href="#pulmonary" class="category-link">
            <span class="category-icon">ü´Å</span>
            <span class="category-name">Pulmonary</span>
            <span class="category-count">7</span>
        </a>
        <a href="#nephrology" class="category-link">
            <span class="category-icon">üíß</span>
            <span class="category-name">Nephrology</span>
            <span class="category-count">15</span>
        </a>
        <a href="#neurology" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Neurology</span>
            <span class="category-count">18</span>
        </a>
        <a href="#pain" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Pain/Anti-inflammatory</span>
            <span class="category-count">27</span>
        </a>
        <a href="#sedatives" class="category-link">
            <span class="category-icon">üò¥</span>
            <span class="category-name">Sedatives/Anxiolytics</span>
            <span class="category-count">10</span>
        </a>
        <a href="#antipsychotics" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Antipsychotics</span>
            <span class="category-count">8</span>
        </a>
        <a href="#antidepressants" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Antidepressants</span>
            <span class="category-count">17</span>
        </a>
        <a href="#anticonvulsants" class="category-link">
            <span class="category-icon">‚ö°</span>
            <span class="category-name">Anticonvulsants</span>
            <span class="category-count">14</span>
        </a>
        <a href="#thyroid" class="category-link">
            <span class="category-icon">ü¶ã</span>
            <span class="category-name">Thyroid</span>
            <span class="category-count">5</span>
        </a>
        <a href="#bone-calcium" class="category-link">
            <span class="category-icon">ü¶¥</span>
            <span class="category-name">Bone/Calcium</span>
            <span class="category-count">13</span>
        </a>
        <a href="#gout" class="category-link">
            <span class="category-icon">ü¶∂</span>
            <span class="category-name">Gout/Uric Acid</span>
            <span class="category-count">7</span>
        </a>
        <a href="#electrolytes" class="category-link">
            <span class="category-icon">‚ö°</span>
            <span class="category-name">Electrolyte Replacement</span>
            <span class="category-count">8</span>
        </a>
        <a href="#hematology" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Hematology</span>
            <span class="category-count">14</span>
        </a>
        <a href="#toxicology" class="category-link">
            <span class="category-icon">‚ò†Ô∏è</span>
            <span class="category-name">Toxicology/Antidotes</span>
            <span class="category-count">20</span>
        </a>
        <a href="#anesthesia" class="category-link">
            <span class="category-icon">üíâ</span>
            <span class="category-name">Anesthesia/Paralytics</span>
            <span class="category-count">8</span>
        </a>
    </div>
</div>


<!-- ======================= ANTIBIOTICS - PENICILLINS ======================= -->
<div class="drug-category" id="antibiotics-penicillins">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Penicillins</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">
        
        <!-- PENICILLIN G -->
        <div class="drug-card" data-search="penicillin g benzylpenicillin streptococcal pharyngitis syphilis endocarditis beta-lactam cell wall">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Penicillin G</span>
                <span class="drug-brand">(Benzylpenicillin)</span>
                <span class="drug-class-badge">Œ≤-Lactam</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds penicillin-binding proteins (PBPs), inhibiting cell wall synthesis ‚Üí bactericidal</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Streptococci (GAS, GBS, viridans), <em>Treponema pallidum</em></li>
                            <li><strong>Key uses:</strong> Strep pharyngitis, syphilis (all stages), native valve endocarditis (strep), neurosyphilis</li>
                            <li><strong>Not active:</strong> Staph aureus (penicillinase producers), most gram-negatives</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Strep pharyngitis</td><td>Pen VK 500mg PO BID-TID √ó 10 days</td></tr>
                            <tr><td>Syphilis (primary/secondary)</td><td>Benzathine PCN G 2.4 MU IM √ó 1</td></tr>
                            <tr><td>Neurosyphilis</td><td>Aqueous PCN G 3-4 MU IV q4h √ó 10-14 days</td></tr>
                            <tr><td>Strep endocarditis</td><td>PCN G 12-18 MU/day IV divided q4h √ó 4 weeks</td></tr>
                        </table>
                        <p><strong>Renal adjustment:</strong> CrCl &lt;10: reduce dose 25-50%</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypersensitivity reactions (rash, anaphylaxis ~0.01%)</li>
                            <li>Jarisch-Herxheimer reaction (syphilis treatment)</li>
                            <li>High-dose: seizures, interstitial nephritis, hyperkalemia (K+ in PCN G potassium)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Cross-reactivity with cephalosporins ~1-2% (much lower than previously thought). Safe to use cephalosporins in most PCN allergies unless severe IgE-mediated reaction.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Syphilis</a>
                </div>
            </div>
        </div>

        <!-- AMPICILLIN -->
        <div class="drug-card" data-search="ampicillin aminopenicillin listeria enterococcus meningitis beta-lactam cell wall">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ampicillin</span>
                <span class="drug-brand">(Principen)</span>
                <span class="drug-class-badge">Aminopenicillin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam; broader gram-negative coverage than PCN G due to enhanced outer membrane penetration</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Key coverage:</strong> <em>Listeria monocytogenes</em>, <em>Enterococcus faecalis</em>, <em>E. coli</em> (some), <em>H. influenzae</em> (non-Œ≤-lactamase)</li>
                            <li><strong>Primary uses:</strong> Listeria meningitis, enterococcal endocarditis, GBS prophylaxis</li>
                            <li><strong>Combination therapy:</strong> + gentamicin for enterococcal endocarditis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Listeria meningitis</td><td>2g IV q4h √ó 21 days</td></tr>
                            <tr><td>Enterococcal endocarditis</td><td>2g IV q4h + gentamicin √ó 4-6 weeks</td></tr>
                            <tr><td>GBS prophylaxis (labor)</td><td>2g IV then 1g q4h until delivery</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Maculopapular rash (especially in EBV infection - NOT true allergy)</li>
                            <li>Diarrhea, <em>C. difficile</em></li>
                            <li>Allergic interstitial nephritis</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">High incidence of rash if given to patients with mononucleosis (EBV) - this is NOT a true penicillin allergy</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Listeria</a>
                </div>
            </div>
        </div>

        <!-- AMPICILLIN-SULBACTAM -->
        <div class="drug-card" data-search="ampicillin sulbactam unasyn aspiration pneumonia diabetic foot beta-lactamase inhibitor">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ampicillin-Sulbactam</span>
                <span class="drug-brand">(Unasyn)</span>
                <span class="drug-class-badge">Œ≤-Lactam/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Sulbactam inhibits Œ≤-lactamases ‚Üí restores ampicillin activity. Sulbactam itself has activity against <em>Acinetobacter</em></div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Extended coverage:</strong> MSSA, anaerobes (Bacteroides), Œ≤-lactamase producing organisms</li>
                            <li><strong>Key uses:</strong> Aspiration pneumonia, diabetic foot infections (mild-moderate), skin/soft tissue, intra-abdominal</li>
                            <li><strong>Unique:</strong> <em>Acinetobacter baumannii</em> (due to sulbactam)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3g IV q6h</td></tr>
                            <tr><td>Acinetobacter</td><td>3g IV q4h or 9g/day continuous</td></tr>
                            <tr><td>CrCl 15-29</td><td>1.5g IV q12h</td></tr>
                            <tr><td>CrCl &lt;15</td><td>1.5g IV q24h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Sulbactam component has intrinsic activity against Acinetobacter - use high-dose sulbactam (9g/day) for MDR Acinetobacter infections</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#diabetic-foot-infection" class="guide-link">IMCRG: Diabetic Foot</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Aspiration PNA</a>
                </div>
            </div>
        </div>

        <!-- PIPERACILLIN-TAZOBACTAM -->
        <div class="drug-card" data-search="piperacillin tazobactam zosyn pip-tazo pseudomonas nosocomial pneumonia neutropenic fever broad spectrum">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Piperacillin-Tazobactam</span>
                <span class="drug-brand">(Zosyn)</span>
                <span class="drug-class-badge">Extended-Spectrum PCN/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Piperacillin: extended-spectrum penicillin with anti-pseudomonal activity. Tazobactam: Œ≤-lactamase inhibitor restoring activity against ESBL producers (variable)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep, enterococci (not VRE), MSSA</li>
                            <li><strong>Gram-negative:</strong> <em>Pseudomonas aeruginosa</em>, Enterobacterales, <em>H. influenzae</em></li>
                            <li><strong>Anaerobes:</strong> Excellent (Bacteroides, etc.)</li>
                            <li><strong>Key uses:</strong> Nosocomial pneumonia, neutropenic fever, intra-abdominal infections, diabetic foot</li>
                            <li><strong>Gaps:</strong> MRSA, Stenotrophomonas, atypicals, some ESBL producers</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3.375g IV q6h</td></tr>
                            <tr><td>Pseudomonas/severe</td><td>4.5g IV q6h (or 3.375g q6h extended infusion 4hr)</td></tr>
                            <tr><td>CrCl 20-40</td><td>2.25g IV q6h</td></tr>
                            <tr><td>CrCl &lt;20</td><td>2.25g IV q8h</td></tr>
                            <tr><td>HD</td><td>2.25g IV q8h + 0.75g after HD</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> Infuse over 4 hours to maximize time above MIC - superior PK/PD</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypokalemia (monitor K+)</li>
                            <li>Leukopenia, thrombocytopenia (prolonged use >14 days)</li>
                            <li>Nephrotoxicity when combined with vancomycin (controversial - likely AIN)</li>
                            <li>Seizures (high doses, renal impairment)</li>
                            <li><em>C. difficile</em> colitis</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Pip-tazo + vancomycin associated with increased AKI compared to cefepime + vancomycin. Consider alternatives if possible.</div>
                <div class="pearl-box">Extended infusion (4hr) is pharmacokinetically superior for serious infections - increases time above MIC</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html#empiric-therapy" class="guide-link">ID Guide: Empiric Therapy</a>
                </div>
            </div>
        </div>

        <!-- NAFCILLIN -->
        <div class="drug-card" data-search="nafcillin antistaphylococcal mssa endocarditis osteomyelitis penicillinase-resistant">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Nafcillin</span>
                <span class="drug-brand">(Nallpen)</span>
                <span class="drug-class-badge">Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Penicillinase-resistant penicillin; resists staph Œ≤-lactamase (not MRSA mecA)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Primary target:</strong> MSSA - drug of choice for serious MSSA infections</li>
                            <li><strong>Key uses:</strong> MSSA bacteremia, endocarditis, osteomyelitis, septic arthritis</li>
                            <li><strong>NOT for:</strong> MRSA, enterococci, gram-negatives</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>MSSA endocarditis</td><td>2g IV q4h √ó 6 weeks</td></tr>
                            <tr><td>MSSA bacteremia</td><td>2g IV q4h √ó 2-4 weeks</td></tr>
                            <tr><td>Osteomyelitis</td><td>2g IV q4h √ó 4-6 weeks</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> - hepatic metabolism</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Phlebitis (use central line for prolonged therapy)</li>
                            <li>Interstitial nephritis (AIN)</li>
                            <li>Neutropenia (with prolonged use - check CBC weekly)</li>
                            <li>Hepatotoxicity</li>
                            <li>Drug-induced fever</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Nafcillin/oxacillin are preferred over vancomycin for serious MSSA infections - better outcomes, faster clearance of bacteremia</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="im_guidev3B20.html#osteomyelitis" class="guide-link">IMCRG: Osteomyelitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: MSSA</a>
                </div>
            </div>
        </div>

        <!-- OXACILLIN -->
        <div class="drug-card" data-search="oxacillin antistaphylococcal mssa penicillinase-resistant">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Oxacillin</span>
                <span class="drug-brand">(Bactocill)</span>
                <span class="drug-class-badge">Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Penicillinase-resistant penicillin; equivalent to nafcillin for MSSA</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Same as nafcillin - MSSA coverage</li>
                            <li>Alternative to nafcillin with similar efficacy</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>2g IV q4h (same as nafcillin)</p>
                        <p>Requires renal adjustment (unlike nafcillin)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar to nafcillin</li>
                            <li>Higher rate of hepatotoxicity than nafcillin</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>

        <!-- DICLOXACILLIN -->
        <div class="drug-card" data-search="dicloxacillin oral mssa cellulitis skin soft tissue">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dicloxacillin</span>
                <span class="drug-brand">(Dynapen)</span>
                <span class="drug-class-badge">Oral Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Oral penicillinase-resistant penicillin for MSSA</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>MSSA skin/soft tissue infections</li>
                            <li>Step-down therapy from IV nafcillin/oxacillin</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>500mg PO QID (take on empty stomach)</p>
                        <p>Duration: 5-10 days for uncomplicated SSTI</p>
                    </div>
                </div>
                <div class="pearl-box">Must take on empty stomach (1hr before or 2hr after meals) - food significantly reduces absorption</div>
            </div>
        </div>

        <!-- AMOXICILLIN -->
        <div class="drug-card" data-search="amoxicillin aminopenicillin sinusitis otitis pharyngitis helicobacter">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amoxicillin</span>
                <span class="drug-brand">(Amoxil)</span>
                <span class="drug-class-badge">Aminopenicillin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Oral aminopenicillin; better absorbed than ampicillin</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Strep pharyngitis, sinusitis, otitis media</li>
                            <li>Community-acquired pneumonia (in combination)</li>
                            <li><em>H. pylori</em> triple therapy component</li>
                            <li>Endocarditis prophylaxis (dental procedures)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Strep pharyngitis</td><td>500mg PO BID or 1g PO daily √ó 10 days</td></tr>
                            <tr><td>Sinusitis</td><td>500mg PO TID or 875mg PO BID √ó 5-10 days</td></tr>
                            <tr><td>H. pylori (triple)</td><td>1g PO BID √ó 14 days</td></tr>
                            <tr><td>Endocarditis prophylaxis</td><td>2g PO 30-60 min before procedure</td></tr>
                        </table>
                    </div>
                </div>
            </div>
        </div>

        <!-- AMOXICILLIN-CLAVULANATE -->
        <div class="drug-card" data-search="amoxicillin clavulanate augmentin bite wounds sinusitis diabetic foot beta-lactamase inhibitor">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amoxicillin-Clavulanate</span>
                <span class="drug-brand">(Augmentin)</span>
                <span class="drug-class-badge">Aminopenicillin/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Clavulanate inhibits Œ≤-lactamases ‚Üí extends amoxicillin spectrum</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Extended coverage:</strong> MSSA, Œ≤-lactamase producing H. influenzae, M. catarrhalis, anaerobes</li>
                            <li><strong>Key uses:</strong> Bite wounds (human/animal), acute sinusitis, UTI, mild diabetic foot, aspiration PNA</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>875/125mg PO BID</td></tr>
                            <tr><td>Severe/respiratory</td><td>2000/125mg (XR) PO BID</td></tr>
                            <tr><td>Bite wounds</td><td>875/125mg PO BID √ó 3-5 days (prophylaxis) or 5-10 days (treatment)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Diarrhea</strong> (clavulanate dose-dependent - use BID formulations)</li>
                            <li>Hepatotoxicity (cholestatic - "Augmentin hepatitis")</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Bite wounds (cat, dog, human) - Augmentin is first-line. Cat bites have highest infection rate. Cover Pasteurella, oral anaerobes, and staph/strep.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: Skin/Soft Tissue</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Bite Wounds</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIBIOTICS - CEPHALOSPORINS ======================= -->
<div class="drug-category" id="antibiotics-cephalosporins">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Cephalosporins</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- CEFAZOLIN -->
        <div class="drug-card" data-search="cefazolin ancef first generation surgical prophylaxis mssa cellulitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefazolin</span>
                <span class="drug-brand">(Ancef, Kefzol)</span>
                <span class="drug-class-badge">1st Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam; binds PBPs, inhibits cell wall synthesis. Best gram-positive coverage of cephalosporins.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> MSSA (excellent), Streptococci</li>
                            <li><strong>Gram-negative:</strong> E. coli, Klebsiella, Proteus (limited)</li>
                            <li><strong>Key uses:</strong> Surgical prophylaxis (#1), MSSA infections, UTI, SSTI</li>
                            <li><strong>Alternative to nafcillin</strong> for MSSA with slightly less efficacy but better tolerability</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Surgical prophylaxis</td><td>2g IV within 60 min of incision (redose q4h if prolonged)</td></tr>
                            <tr><td>MSSA bacteremia</td><td>2g IV q8h</td></tr>
                            <tr><td>Skin/soft tissue</td><td>1-2g IV q8h</td></tr>
                            <tr><td>CrCl 35-54</td><td>1g IV q8h</td></tr>
                            <tr><td>CrCl 11-34</td><td>500mg IV q12h</td></tr>
                            <tr><td>CrCl ‚â§10</td><td>500mg IV q24h</td></tr>
                        </table>
                        <p><strong>Weight-based surgical prophylaxis:</strong> 2g if &lt;120kg, 3g if ‚â•120kg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Generally well-tolerated</li>
                            <li>Cross-reactivity with penicillins ~1-2%</li>
                            <li>Interstitial nephritis (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Cefazolin can be used for most MSSA infections as alternative to nafcillin. Data for MSSA endocarditis is emerging but nafcillin remains standard.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: SSTI</a>
                    <a href="id_guide5_5_integrated.html#surgical-prophylaxis" class="guide-link">ID Guide: Surgical Prophylaxis</a>
                </div>
            </div>
        </div>

        <!-- CEPHALEXIN -->
        <div class="drug-card" data-search="cephalexin keflex oral first generation cellulitis uti skin">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cephalexin</span>
                <span class="drug-brand">(Keflex)</span>
                <span class="drug-class-badge">1st Gen (Oral)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Oral equivalent of cefazolin</li>
                            <li><strong>Key uses:</strong> Non-purulent cellulitis, uncomplicated UTI, strep pharyngitis (PCN allergy)</li>
                            <li>Step-down from IV cefazolin</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Cellulitis</td><td>500mg PO QID √ó 5-10 days</td></tr>
                            <tr><td>UTI (uncomplicated)</td><td>500mg PO BID √ó 3-7 days</td></tr>
                            <tr><td>Strep pharyngitis</td><td>500mg PO BID √ó 10 days</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Non-purulent cellulitis (no abscess) = strep > staph ‚Üí cephalexin is appropriate. Purulent cellulitis (abscess, pus) = staph likely ‚Üí needs MRSA coverage (TMP-SMX, doxy)</div>
            </div>
        </div>

        <!-- CEFTRIAXONE -->
        <div class="drug-card" data-search="ceftriaxone rocephin third generation meningitis pneumonia gonorrhea once daily long half-life">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftriaxone</span>
                <span class="drug-brand">(Rocephin)</span>
                <span class="drug-class-badge">3rd Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">3rd generation cephalosporin with excellent gram-negative coverage and CSF penetration. Long half-life allows once-daily dosing.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep (including S. pneumoniae), but NOT MSSA (poor coverage)</li>
                            <li><strong>Gram-negative:</strong> Excellent - E. coli, Klebsiella, Proteus, H. influenzae, N. meningitidis, N. gonorrhoeae</li>
                            <li><strong>Key uses:</strong> CAP, meningitis, gonorrhea, pyelonephritis, Lyme disease, SBP prophylaxis</li>
                            <li><strong>Gaps:</strong> Pseudomonas, ESBL producers, Enterococcus, Listeria, anaerobes</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>1-2g IV daily + azithromycin</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q12h</td></tr>
                            <tr><td>Gonorrhea</td><td>500mg IM √ó 1 (if &lt;150kg) or 1g IM √ó 1 (if ‚â•150kg)</td></tr>
                            <tr><td>Pyelonephritis</td><td>1g IV daily</td></tr>
                            <tr><td>Lyme disease (neuro/cardiac)</td><td>2g IV daily √ó 14-28 days</td></tr>
                            <tr><td>SBP prophylaxis</td><td>1g IV daily or 400mg PO norfloxacin daily</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> (hepatic/biliary excretion)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Biliary sludging/pseudolithiasis (especially prolonged high doses)</li>
                            <li><strong>Do NOT mix with calcium-containing solutions</strong> (precipitates)</li>
                            <li>Ceftriaxone-induced hemolytic anemia (rare but serious)</li>
                            <li>Vitamin K antagonism (prolonged PT/INR)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Do NOT use with calcium-containing IV solutions (precipitation). In neonates, avoid coadministration with calcium products.</div>
                <div class="pearl-box">Ceftriaxone does NOT cover MSSA well - don't use alone for staph infections. Add vancomycin for empiric MRSA coverage.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="im_guidev3B20.html#sbp" class="guide-link">IMCRG: SBP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CEFEPIME -->
        <div class="drug-card" data-search="cefepime maxipime fourth generation pseudomonas neutropenic fever hap nosocomial">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefepime</span>
                <span class="drug-brand">(Maxipime)</span>
                <span class="drug-class-badge">4th Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">4th generation with enhanced stability against AmpC Œ≤-lactamases and anti-pseudomonal activity. Zwitterionic structure ‚Üí rapid penetration.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Good strep coverage, MSSA (better than CTX)</li>
                            <li><strong>Gram-negative:</strong> Excellent including <em>Pseudomonas aeruginosa</em></li>
                            <li><strong>AmpC stability:</strong> Active against Enterobacter, Citrobacter, Serratia</li>
                            <li><strong>Key uses:</strong> Neutropenic fever, HAP/VAP, complicated UTI, meningitis</li>
                            <li><strong>Gaps:</strong> MRSA, anaerobes, ESBL producers, Acinetobacter</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Neutropenic fever</td><td>2g IV q8h</td></tr>
                            <tr><td>HAP/VAP</td><td>2g IV q8h</td></tr>
                            <tr><td>Complicated UTI</td><td>1-2g IV q12h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 30-60</td><td>2g IV q12h</td></tr>
                            <tr><td>CrCl 11-29</td><td>2g IV q24h</td></tr>
                            <tr><td>CrCl ‚â§10 or HD</td><td>1g IV q24h</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> 2g over 3-4 hours improves PK/PD</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Neurotoxicity:</strong> Encephalopathy, seizures, myoclonus (especially with renal impairment - MUST dose adjust)</li>
                            <li>Rash, diarrhea</li>
                            <li>Positive Coombs test</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Cefepime neurotoxicity: Patients with renal impairment at high risk for encephalopathy, myoclonus, seizures. ALWAYS adjust dose for renal function.</div>
                <div class="pearl-box">Cefepime is stable against AmpC Œ≤-lactamases (SPACE organisms: Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter) - use for Enterobacter infections instead of 3rd gen cephalosporins.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#neutropenic-fever" class="guide-link">IMCRG: Neutropenic Fever</a>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CEFTAZIDIME -->
        <div class="drug-card" data-search="ceftazidime fortaz tazicef third generation pseudomonas meningitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftazidime</span>
                <span class="drug-brand">(Fortaz, Tazicef)</span>
                <span class="drug-class-badge">3rd Gen (Anti-Pseudomonal)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Key feature:</strong> Anti-pseudomonal 3rd generation cephalosporin</li>
                            <li>Excellent gram-negative coverage including Pseudomonas</li>
                            <li><strong>Weak gram-positive coverage</strong> (weaker than ceftriaxone)</li>
                            <li><strong>Uses:</strong> Pseudomonal infections, meningitis, CF exacerbations</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Pseudomonas infections</td><td>2g IV q8h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 31-50</td><td>1g IV q12h</td></tr>
                            <tr><td>CrCl 16-30</td><td>1g IV q24h</td></tr>
                            <tr><td>CrCl ‚â§15</td><td>500mg IV q24h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Ceftazidime has WEAK gram-positive activity - do not use as monotherapy when gram-positives are suspected</div>
            </div>
        </div>

        <!-- CEFOTAXIME -->
        <div class="drug-card" data-search="cefotaxime claforan third generation meningitis neonates">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefotaxime</span>
                <span class="drug-brand">(Claforan)</span>
                <span class="drug-class-badge">3rd Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar to ceftriaxone but shorter half-life (q8h dosing)</li>
                            <li><strong>Preferred in neonates</strong> (no biliary sludging like ceftriaxone)</li>
                            <li>Meningitis, serious gram-negative infections</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>1-2g IV q6-8h</p>
                        <p>Meningitis: 2g IV q4-6h</p>
                    </div>
                </div>
            </div>
        </div>

        <!-- CEFTAROLINE -->
        <div class="drug-card" data-search="ceftaroline teflaro fifth generation mrsa cap ssti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftaroline</span>
                <span class="drug-brand">(Teflaro)</span>
                <span class="drug-class-badge">5th Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds PBP2a (mecA-encoded) ‚Üí activity against MRSA. Only Œ≤-lactam with MRSA activity.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Unique feature:</strong> MRSA coverage (only cephalosporin)</li>
                            <li>Also covers MSSA, Strep (including PRSP), common gram-negatives</li>
                            <li><strong>FDA indications:</strong> CAP, acute bacterial skin/soft tissue infections</li>
                            <li><strong>NOT anti-pseudomonal</strong></li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>600mg IV q12h √ó 5-7 days</td></tr>
                            <tr><td>ABSSSI</td><td>600mg IV q12h √ó 5-14 days</td></tr>
                            <tr><td>CrCl 31-50</td><td>400mg IV q12h</td></tr>
                            <tr><td>CrCl 15-30</td><td>300mg IV q12h</td></tr>
                            <tr><td>HD</td><td>200mg IV q12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Ceftaroline is the only Œ≤-lactam with MRSA activity. Consider for MRSA pneumonia as alternative to vancomycin/linezolid.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - CARBAPENEMS ======================= -->
<div class="drug-category" id="antibiotics-carbapenems">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Carbapenems</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- MEROPENEM -->
        <div class="drug-card" data-search="meropenem merrem carbapenem broad spectrum esbl meningitis seizure">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Meropenem</span>
                <span class="drug-brand">(Merrem)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam with broadest spectrum; stable against most Œ≤-lactamases including ESBLs and AmpC. Binds PBP2.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Broadest Œ≤-lactam spectrum:</strong> Gram-positive (not MRSA, not Enterococcus faecium), Gram-negative (including Pseudomonas, ESBL producers), Anaerobes</li>
                            <li><strong>Key uses:</strong> ESBL infections, severe nosocomial infections, meningitis (best CNS penetration), neutropenic fever</li>
                            <li><strong>Gaps:</strong> MRSA, VRE, <em>Stenotrophomonas</em>, atypicals, carbapenem-resistant organisms (CRE)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>1g IV q8h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>Pseudomonas/severe</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 26-50</td><td>1g IV q12h</td></tr>
                            <tr><td>CrCl 10-25</td><td>500mg IV q12h</td></tr>
                            <tr><td>CrCl &lt;10</td><td>500mg IV q24h</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> 3-hour infusion improves PK/PD for serious infections</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Seizures (lower risk than imipenem)</li>
                            <li>Diarrhea, <em>C. difficile</em></li>
                            <li>Rash</li>
                            <li>Drug interactions: lowers valproic acid levels significantly</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Carbapenems dramatically lower valproic acid levels (up to 80% reduction) ‚Üí seizure risk. Avoid combination or use alternative antibiotic.</div>
                <div class="pearl-box">Meropenem preferred over imipenem for CNS infections - better CSF penetration and lower seizure threshold.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: ESBL</a>
                </div>
            </div>
        </div>

        <!-- IMIPENEM-CILASTATIN -->
        <div class="drug-card" data-search="imipenem cilastatin primaxin carbapenem broad spectrum seizure">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Imipenem-Cilastatin</span>
                <span class="drug-brand">(Primaxin)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Imipenem = carbapenem antibiotic. Cilastatin = inhibits renal dehydropeptidase (prevents imipenem degradation in kidneys)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar broad spectrum to meropenem</li>
                            <li><strong>Slightly better Enterococcus faecalis coverage</strong></li>
                            <li>Nosocomial infections, polymicrobial infections</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>500mg IV q6h</td></tr>
                            <tr><td>Severe/Pseudomonas</td><td>1g IV q6-8h</td></tr>
                            <tr><td>CrCl 41-70</td><td>500mg IV q8h</td></tr>
                            <tr><td>CrCl 21-40</td><td>250-500mg IV q6-12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Highest seizure risk of carbapenems</strong> (avoid in CNS infections)</li>
                            <li>Nausea/vomiting (more than meropenem)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Imipenem has the HIGHEST seizure risk among carbapenems. Avoid in CNS infections and patients with seizure history. Use meropenem instead.</div>
            </div>
        </div>

        <!-- ERTAPENEM -->
        <div class="drug-card" data-search="ertapenem invanz carbapenem once daily outpatient esbl no pseudomonas">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ertapenem</span>
                <span class="drug-brand">(Invanz)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Once-daily carbapenem. Long half-life allows outpatient parenteral therapy (OPAT).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Similar to meropenem EXCEPT:</strong> NO Pseudomonas activity, NO Acinetobacter activity</li>
                            <li>Excellent for ESBL producers</li>
                            <li><strong>Key uses:</strong> ESBL UTI/intra-abdominal, community infections, OPAT</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard</td><td>1g IV/IM daily</td></tr>
                            <tr><td>CrCl &lt;30</td><td>500mg IV daily</td></tr>
                        </table>
                        <p>Can give IM for OPAT (mix with lidocaine)</p>
                    </div>
                </div>
                <div class="pearl-box">Ertapenem has NO Pseudomonas coverage - do not use for suspected Pseudomonas infections. Great for OPAT due to once-daily dosing.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIBIOTICS - GLYCOPEPTIDES ======================= -->
<div class="drug-category" id="antibiotics-glycopeptides">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Glycopeptides & Lipoglycopeptides</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- VANCOMYCIN -->
        <div class="drug-card" data-search="vancomycin mrsa clostridium difficile cdiff gram positive trough nephrotoxicity red man">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Vancomycin</span>
                <span class="drug-brand">(Vancocin)</span>
                <span class="drug-class-badge">Glycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds D-Ala-D-Ala terminus of peptidoglycan precursors ‚Üí inhibits cell wall synthesis. Time-dependent killing with AUC/MIC target.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive only:</strong> MRSA, MSSA (if PCN allergic), coagulase-negative staph, Strep (including PCN-resistant), Enterococcus (not VRE)</li>
                            <li><strong>IV uses:</strong> MRSA bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia, skin/soft tissue</li>
                            <li><strong>Oral vancomycin:</strong> <em>C. difficile</em> infection (NOT absorbed - local effect only)</li>
                            <li><strong>Gaps:</strong> Gram-negatives, VRE, atypicals</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Indication</th><th>Dose</th></tr>
                            <tr><td rowspan="3">IV</td><td>Loading dose</td><td>25-30 mg/kg (actual body weight) √ó 1</td></tr>
                            <tr><td>Maintenance</td><td>15-20 mg/kg q8-12h (adjust to AUC 400-600)</td></tr>
                            <tr><td>CrCl &lt;50</td><td>Extend interval or use AUC-guided dosing</td></tr>
                            <tr><td rowspan="2">PO</td><td>C. diff (non-severe)</td><td>125mg PO QID √ó 10 days</td></tr>
                            <tr><td>C. diff (severe)</td><td>500mg PO QID + metronidazole 500mg IV q8h</td></tr>
                        </table>
                        <p><strong>AUC-guided dosing:</strong> Target AUC/MIC 400-600 (replaces trough-based dosing per 2020 guidelines)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>AUC-guided dosing preferred</strong> over trough-only monitoring</li>
                            <li>If using troughs: target 15-20 mcg/mL for serious MRSA infections</li>
                            <li>Renal function (SCr) - monitor closely with concomitant nephrotoxins</li>
                            <li>Trough before 4th dose (steady state)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Red Man Syndrome:</strong> Histamine release from rapid infusion ‚Üí flushing, pruritus, hypotension. NOT an allergy. Prevent with slower infusion (‚â•1hr for 1g)</li>
                            <li><strong>Nephrotoxicity:</strong> Risk increases with high troughs, prolonged therapy, concomitant nephrotoxins (pip-tazo, aminoglycosides)</li>
                            <li>Ototoxicity (rare, usually with high doses)</li>
                            <li>Neutropenia (prolonged use >2 weeks - check CBC weekly)</li>
                            <li>DRESS syndrome (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Infuse over ‚â•60 minutes (‚â•1g) or ‚â•90 minutes (>1g) to prevent Red Man Syndrome. This is a histamine reaction, NOT an allergy.</div>
                <div class="pearl-box">Oral vancomycin is NOT absorbed systemically - use ONLY for C. difficile colitis. IV vancomycin does NOT reach therapeutic levels in the colon.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cdiff" class="guide-link">IMCRG: C. diff</a>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html#mrsa" class="guide-link">ID Guide: MRSA</a>
                    <a href="nephrology_study_guide1.html#drugs" class="guide-link">Nephro: Drug Dosing</a>
                </div>
            </div>
        </div>

        <!-- DALBAVANCIN -->
        <div class="drug-card" data-search="dalbavancin dalvance lipoglycopeptide mrsa long-acting opat single dose">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dalbavancin</span>
                <span class="drug-brand">(Dalvance)</span>
                <span class="drug-class-badge">Lipoglycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Lipoglycopeptide with ultra-long half-life (~14 days). Same mechanism as vancomycin but lipophilic tail enhances potency and duration.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Coverage:</strong> MRSA, MSSA, Streptococci (similar to vancomycin)</li>
                            <li><strong>FDA indication:</strong> Acute bacterial skin/soft tissue infections</li>
                            <li><strong>Off-label:</strong> Osteomyelitis, endocarditis (emerging data)</li>
                            <li><strong>Advantage:</strong> Single or two-dose treatment (outpatient friendly)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Regimen</th><th>Dose</th></tr>
                            <tr><td>Single-dose</td><td>1500mg IV √ó 1</td></tr>
                            <tr><td>Two-dose</td><td>1000mg IV day 1, then 500mg IV day 8</td></tr>
                            <tr><td>CrCl &lt;30 (not on HD)</td><td>1125mg IV √ó 1 or 750mg then 375mg</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Dalbavancin allows completion of MRSA treatment with 1-2 IV doses - ideal for patients with adherence concerns, IV access issues, or preference to avoid daily antibiotics.</div>
            </div>
        </div>

        <!-- ORITAVANCIN -->
        <div class="drug-card" data-search="oritavancin orbactiv lipoglycopeptide mrsa single dose ssti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Oritavancin</span>
                <span class="drug-brand">(Orbactiv)</span>
                <span class="drug-class-badge">Lipoglycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Single-dose lipoglycopeptide for MRSA SSTI</li>
                            <li>Similar coverage to dalbavancin</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>1200mg IV √ó 1 (infuse over 3 hours)</p>
                    </div>
                </div>
                <div class="warning-box">Oritavancin interferes with coagulation tests (PT/INR, aPTT) for up to 5 days after administration - use alternative anticoagulation monitoring if needed.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - FLUOROQUINOLONES ======================= -->
<div class="drug-category" id="antibiotics-fluoroquinolones">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Fluoroquinolones</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- CIPROFLOXACIN -->
        <div class="drug-card" data-search="ciprofloxacin cipro fluoroquinolone uti pseudomonas traveler diarrhea anthrax tendon">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ciprofloxacin</span>
                <span class="drug-brand">(Cipro)</span>
                <span class="drug-class-badge">Fluoroquinolone</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV ‚Üí bactericidal. Concentration-dependent killing.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-negative:</strong> Excellent - E. coli, Klebsiella, Proteus, <em>Pseudomonas aeruginosa</em></li>
                            <li><strong>Atypicals:</strong> Legionella</li>
                            <li><strong>Gram-positive:</strong> POOR (except some activity vs Bacillus anthracis)</li>
                            <li><strong>Key uses:</strong> UTI/pyelonephritis, Pseudomonal infections, traveler's diarrhea, anthrax</li>
                            <li><strong>Gaps:</strong> S. pneumoniae (weak), MRSA, anaerobes</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Uncomplicated UTI</td><td>250mg PO BID √ó 3 days</td></tr>
                            <tr><td>Complicated UTI/pyelonephritis</td><td>500mg PO BID or 400mg IV q12h √ó 7-14 days</td></tr>
                            <tr><td>Pseudomonal infections</td><td>750mg PO BID or 400mg IV q8h</td></tr>
                            <tr><td>Traveler's diarrhea</td><td>500mg PO BID √ó 1-3 days</td></tr>
                            <tr><td>CrCl &lt;30</td><td>Reduce dose by 50%</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Tendinopathy/rupture</strong> (especially Achilles, especially with steroids, elderly, renal impairment)</li>
                            <li><strong>QTc prolongation</strong></li>
                            <li>Peripheral neuropathy (may be irreversible)</li>
                            <li>CNS effects: headache, insomnia, seizures</li>
                            <li>Hypoglycemia (especially in diabetics on sulfonylureas)</li>
                            <li>Aortic aneurysm/dissection (rare)</li>
                            <li>Photosensitivity</li>
                            <li><em>C. difficile</em></li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">FDA Black Box Warning: Tendinitis/rupture, peripheral neuropathy, CNS effects, exacerbation of myasthenia gravis, aortic aneurysm. Reserve for when no alternatives available.</div>
                <div class="warning-box">Do NOT give with cations (calcium, magnesium, aluminum, iron) - chelation significantly reduces absorption. Separate by 2-6 hours.</div>
                <div class="pearl-box">Cipro has POOR S. pneumoniae coverage - do NOT use as monotherapy for respiratory infections. Use respiratory FQ (levofloxacin, moxifloxacin) instead.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#uti" class="guide-link">IMCRG: UTI</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Pseudomonas</a>
                </div>
            </div>
        </div>

        <!-- LEVOFLOXACIN -->
        <div class="drug-card" data-search="levofloxacin levaquin respiratory fluoroquinolone cap pneumonia streptococcus">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Levofloxacin</span>
                <span class="drug-brand">(Levaquin)</span>
                <span class="drug-class-badge">Respiratory FQ</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">L-isomer of ofloxacin; "respiratory fluoroquinolone" with enhanced gram-positive activity including S. pneumoniae.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> S. pneumoniae (including PRSP), MSSA</li>
                            <li><strong>Gram-negative:</strong> Similar to cipro, <em>Pseudomonas</em> (but cipro preferred)</li>
                            <li><strong>Atypicals:</strong> Legionella, Mycoplasma, Chlamydia</li>
                            <li><strong>Key uses:</strong> CAP monotherapy, HAP, UTI, sinusitis, chronic bronchitis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>750mg PO/IV daily √ó 5 days</td></tr>
                            <tr><td>HAP</td><td>750mg PO/IV daily √ó 7-14 days</td></tr>
                            <tr><td>UTI (complicated)</td><td>750mg PO/IV daily √ó 5-14 days</td></tr>
                            <tr><td>CrCl 20-49</td><td>750mg q48h or 500mg daily</td></tr>
                            <tr><td>CrCl 10-19</td><td>750mg then 500mg q48h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <p>Same as ciprofloxacin - all FQ class warnings apply</p>
                    </div>
                </div>
                <div class="pearl-box">Levofloxacin is the respiratory FQ of choice when a single agent covering typical and atypical pathogens is needed (CAP monotherapy in PCN-allergic patients).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- MOXIFLOXACIN -->
        <div class="drug-card" data-search="moxifloxacin avelox respiratory fluoroquinolone cap anaerobes qtc">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Moxifloxacin</span>
                <span class="drug-brand">(Avelox)</span>
                <span class="drug-class-badge">Respiratory FQ</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Best gram-positive coverage of FQs (S. pneumoniae, MSSA)</li>
                            <li><strong>Anaerobic activity</strong> (unique among FQs - covers Bacteroides)</li>
                            <li><strong>NO Pseudomonas activity</strong></li>
                            <li><strong>Uses:</strong> CAP, intra-abdominal infections (with anaerobic coverage), TB (MDR)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>400mg PO/IV daily (no renal adjustment needed)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Highest QTc prolongation risk</strong> among FQs</li>
                            <li>All FQ class warnings</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Moxifloxacin has the highest risk of QTc prolongation among FQs. Avoid in patients with baseline QTc prolongation or on other QT-prolonging drugs.</div>
                <div class="pearl-box">Moxifloxacin is the only FQ with clinically useful anaerobic coverage. No Pseudomonas activity - don't use for suspected Pseudomonal infections.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - OTHER ======================= -->
<div class="drug-category" id="antibiotics-other">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Other Classes</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- METRONIDAZOLE -->
        <div class="drug-card" data-search="metronidazole flagyl anaerobes cdiff clostridium giardia trichomonas">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Metronidazole</span>
                <span class="drug-brand">(Flagyl)</span>
                <span class="drug-class-badge">Nitroimidazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Prodrug activated in anaerobic/microaerophilic organisms ‚Üí forms toxic intermediates that damage DNA. Selective for anaerobes.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Anaerobes:</strong> Bacteroides fragilis, Clostridium spp., Fusobacterium, Prevotella</li>
                            <li><strong>Protozoa:</strong> <em>Giardia lamblia</em>, <em>Trichomonas vaginalis</em>, <em>Entamoeba histolytica</em></li>
                            <li><strong>Key uses:</strong> Anaerobic infections, C. diff (second-line), BV, trichomoniasis, giardiasis, H. pylori</li>
                            <li><strong>Gaps:</strong> Aerobes, Actinomyces, Propionibacterium</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Anaerobic infections</td><td>500mg IV/PO q8h</td></tr>
                            <tr><td>C. diff (non-severe, first episode)</td><td>500mg PO TID √ó 10-14 days (vancomycin preferred)</td></tr>
                            <tr><td>Giardiasis</td><td>250mg PO TID √ó 5-7 days</td></tr>
                            <tr><td>Trichomoniasis</td><td>2g PO √ó 1 or 500mg BID √ó 7 days</td></tr>
                            <tr><td>H. pylori (triple therapy)</td><td>500mg PO BID √ó 14 days</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Disulfiram-like reaction with alcohol</strong> (avoid alcohol during and 3 days after)</li>
                            <li>Metallic taste</li>
                            <li>Peripheral neuropathy (prolonged use)</li>
                            <li>Nausea, dark urine</li>
                            <li>CNS effects (seizures with high doses)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Disulfiram-like reaction: Severe nausea, vomiting, flushing, headache with alcohol. Avoid alcohol during therapy and 3 days after completion.</div>
                <div class="pearl-box">For C. diff: Oral vancomycin is now preferred over metronidazole per IDSA guidelines. Metronidazole reserved for when vancomycin unavailable or as adjunct in severe/fulminant disease.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cdiff" class="guide-link">IMCRG: C. diff</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Anaerobes</a>
                </div>
            </div>
        </div>

        <!-- DOXYCYCLINE -->
        <div class="drug-card" data-search="doxycycline tetracycline atypical cap mrsa community lyme tick rickettsial">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Doxycycline</span>
                <span class="drug-brand">(Vibramycin)</span>
                <span class="drug-class-badge">Tetracycline</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 30S ribosomal subunit ‚Üí inhibits protein synthesis. Bacteriostatic.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Atypicals:</strong> Mycoplasma, Chlamydia, Legionella</li>
                            <li><strong>Tick-borne:</strong> Rickettsia (RMSF), Ehrlichia, Anaplasma, Borrelia (Lyme)</li>
                            <li><strong>CA-MRSA:</strong> Variable but often active</li>
                            <li><strong>Other:</strong> Vibrio, Brucella, some Nocardia, malaria prophylaxis</li>
                            <li><strong>Key uses:</strong> CAP (with Œ≤-lactam), MRSA skin infections, Lyme disease, STIs (Chlamydia), tick-borne infections, acne</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Most infections</td><td>100mg PO/IV BID</td></tr>
                            <tr><td>Chlamydia</td><td>100mg PO BID √ó 7 days</td></tr>
                            <tr><td>Lyme (early)</td><td>100mg PO BID √ó 10-21 days</td></tr>
                            <tr><td>RMSF/Ehrlichia</td><td>100mg PO/IV BID √ó 7-14 days</td></tr>
                            <tr><td>CA-MRSA skin</td><td>100mg PO BID √ó 5-10 days</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> (fecal excretion)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Photosensitivity (use sunscreen)</li>
                            <li>GI upset, esophagitis (take with water, stay upright 30 min)</li>
                            <li>Tooth discoloration in children &lt;8 years (avoid in pregnancy)</li>
                            <li>Pill esophagitis (take with full glass of water)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Doxycycline is the drug of choice for ALL tick-borne rickettsial infections (RMSF, Ehrlichia, Anaplasma). Do NOT delay treatment while awaiting diagnostic confirmation - early doxycycline is life-saving.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: SSTI</a>
                    <a href="id_guide5_5_integrated.html#tickborne-infections" class="guide-link">ID Guide: Tick-borne</a>
                </div>
            </div>
        </div>

        <!-- LINEZOLID -->
        <div class="drug-card" data-search="linezolid zyvox oxazolidinone mrsa vre vap pneumonia serotonin mao">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Linezolid</span>
                <span class="drug-brand">(Zyvox)</span>
                <span class="drug-class-badge">Oxazolidinone</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 50S ribosomal subunit at unique site ‚Üí inhibits initiation complex formation. Bacteriostatic (bactericidal vs some strep). Also weak MAO inhibitor.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive only:</strong> MRSA, VRE (including E. faecium), PRSP, VISA/VRSA</li>
                            <li><strong>Key uses:</strong> MRSA pneumonia (may be superior to vanc), VRE infections, serious MRSA when vancomycin not tolerated</li>
                            <li><strong>Excellent oral bioavailability</strong> (~100% - IV and PO equivalent)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>600mg PO/IV q12h (no renal adjustment)</p>
                        <p>Duration depends on infection - typically 10-28 days</p>
                        <p><strong>Limit therapy to ‚â§2 weeks if possible</strong> due to toxicity</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myelosuppression:</strong> Thrombocytopenia (reversible), anemia - monitor CBC weekly</li>
                            <li><strong>Peripheral/optic neuropathy</strong> (prolonged use >28 days)</li>
                            <li><strong>Serotonin syndrome</strong> with SSRIs, SNRIs, MAOIs, meperidine, tramadol</li>
                            <li>Lactic acidosis (rare, prolonged therapy)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Serotonin syndrome risk: Avoid concurrent use with SSRIs, SNRIs, MAOIs, tramadol, meperidine. If unavoidable, monitor closely for serotonin syndrome.</div>
                <div class="pearl-box">Linezolid has 100% oral bioavailability - PO and IV doses are equivalent. Preferred for MRSA pneumonia per some data showing better lung penetration than vancomycin.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: VRE</a>
                </div>
            </div>
        </div>

        <!-- TMP-SMX -->
        <div class="drug-card" data-search="tmp-smx trimethoprim sulfamethoxazole bactrim septra mrsa pcp pneumocystis uti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Trimethoprim-Sulfamethoxazole</span>
                <span class="drug-brand">(Bactrim, Septra)</span>
                <span class="drug-class-badge">Sulfonamide/DHFR Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Sequential blockade of folate synthesis: SMX inhibits dihydropteroate synthase, TMP inhibits dihydrofolate reductase. Synergistic bactericidal effect.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>CA-MRSA:</strong> Excellent oral option</li>
                            <li><strong>PCP:</strong> Drug of choice for <em>Pneumocystis jirovecii</em> pneumonia (treatment and prophylaxis)</li>
                            <li><strong>Gram-negative:</strong> E. coli (UTI), Stenotrophomonas</li>
                            <li><strong>Other:</strong> Nocardia, Listeria, Toxoplasma, Isospora</li>
                            <li><strong>Key uses:</strong> UTI, CA-MRSA skin infections, PCP, Stenotrophomonas</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose (TMP component)</th></tr>
                            <tr><td>UTI (uncomplicated)</td><td>DS (160/800) PO BID √ó 3 days</td></tr>
                            <tr><td>MRSA skin infection</td><td>DS PO BID √ó 5-10 days</td></tr>
                            <tr><td>PCP treatment</td><td>15-20 mg/kg/day TMP IV/PO divided q6-8h √ó 21 days</td></tr>
                            <tr><td>PCP prophylaxis</td><td>DS PO daily or SS PO daily</td></tr>
                            <tr><td>Stenotrophomonas</td><td>5 mg/kg TMP IV q8h</td></tr>
                        </table>
                        <p>DS = double strength (160mg TMP/800mg SMX)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hyperkalemia</strong> (TMP blocks ENaC in collecting duct - similar to amiloride)</li>
                            <li>Elevated creatinine (TMP inhibits creatinine secretion - not true AKI)</li>
                            <li>Rash (common), Stevens-Johnson syndrome (rare but serious)</li>
                            <li>Myelosuppression (megaloblastic anemia, leukopenia)</li>
                            <li>Crystalluria (maintain hydration)</li>
                            <li>Photosensitivity</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">TMP-SMX causes hyperkalemia - monitor K+ especially in patients on ACEi/ARB, renal impairment, or elderly. Creatinine rise is often artifactual (TMP inhibits secretion).</div>
                <div class="pearl-box">TMP-SMX is drug of choice for Stenotrophomonas maltophilia - a pan-resistant gram-negative that is intrinsically resistant to carbapenems.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pcp" class="guide-link">IMCRG: PCP</a>
                    <a href="im_guidev3B20.html#uti" class="guide-link">IMCRG: UTI</a>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CLINDAMYCIN -->
        <div class="drug-card" data-search="clindamycin cleocin anaerobes mssa mrsa community aspiration toxin inhibition">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Clindamycin</span>
                <span class="drug-brand">(Cleocin)</span>
                <span class="drug-class-badge">Lincosamide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 50S ribosome ‚Üí inhibits protein synthesis. Bacteriostatic. Also inhibits toxin production (useful in toxin-mediated diseases).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep (GAS, GBS), MSSA, CA-MRSA (check D-test)</li>
                            <li><strong>Anaerobes above diaphragm:</strong> (not reliable for B. fragilis)</li>
                            <li><strong>Key uses:</strong> Aspiration PNA, necrotizing fasciitis (toxin suppression), skin infections, dental infections</li>
                            <li><strong>Toxin suppression:</strong> Added to Œ≤-lactam for strep/staph toxic shock</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>300-450mg PO TID-QID or 600-900mg IV q8h</td></tr>
                            <tr><td>Severe/toxin-mediated</td><td>900mg IV q8h</td></tr>
                            <tr><td>Necrotizing fasciitis</td><td>900mg IV q8h (added to Œ≤-lactam)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>C. difficile:</strong> Highest risk among antibiotics (historically)</li>
                            <li>Diarrhea (common even without C. diff)</li>
                            <li>Rash</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">High risk of C. difficile colitis - reserve for appropriate indications. Monitor for diarrhea.</div>
                <div class="pearl-box">Add clindamycin for toxin suppression in severe group A strep infections (necrotizing fasciitis, toxic shock) - inhibits bacterial protein/toxin synthesis.</div>
            </div>
        </div>

        <!-- DAPTOMYCIN -->
        <div class="drug-card" data-search="daptomycin cubicin lipopeptide mrsa vre bacteremia endocarditis ck muscle">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Daptomycin</span>
                <span class="drug-brand">(Cubicin)</span>
                <span class="drug-class-badge">Lipopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds bacterial membrane ‚Üí rapid depolarization ‚Üí cell death. Concentration-dependent bactericidal. Unique mechanism - no cross-resistance.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> MRSA, VRE, VISA/VRSA, streptococci</li>
                            <li><strong>Key uses:</strong> MRSA bacteremia, right-sided endocarditis, complicated skin infections, VRE</li>
                            <li><strong>CANNOT use for pneumonia</strong> - inactivated by pulmonary surfactant</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Skin/soft tissue</td><td>4 mg/kg IV daily</td></tr>
                            <tr><td>Bacteremia/endocarditis</td><td>6-10 mg/kg IV daily (higher doses for severe)</td></tr>
                            <tr><td>VRE bacteremia</td><td>8-10 mg/kg IV daily</td></tr>
                            <tr><td>CrCl &lt;30</td><td>Same dose q48h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myopathy/rhabdomyolysis:</strong> Monitor CPK weekly - hold if CPK >10√ó ULN or symptoms</li>
                            <li>Eosinophilic pneumonia (rare)</li>
                            <li>Peripheral neuropathy</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">DO NOT use daptomycin for pneumonia - inactivated by pulmonary surfactant. No activity in the lung.</div>
                <div class="warning-box">Monitor CPK weekly. Hold statins during therapy to reduce myopathy risk. Discontinue if CPK >10√ó ULN or symptomatic myopathy.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: MRSA/VRE</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTICOAGULANTS ======================= -->
<div class="drug-category" id="anticoagulants">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü©∏ Anticoagulants</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- HEPARIN -->
        <div class="drug-card" data-search="heparin unfractionated ufh dvt pe vte acs hit ptt anti-xa">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Unfractionated Heparin (UFH)</span>
                <span class="drug-brand">(Heparin)</span>
                <span class="drug-class-badge">Indirect Thrombin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds antithrombin III ‚Üí potentiates inhibition of thrombin (IIa), Xa, IXa, XIa, XIIa. Requires ATIII for activity.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>VTE treatment (when rapid reversibility needed)</li>
                            <li>ACS (with PCI)</li>
                            <li>Bridging for procedures</li>
                            <li>Cardiopulmonary bypass</li>
                            <li>Preferred in severe renal impairment (no renal clearance)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>VTE treatment</td><td>80 units/kg bolus, then 18 units/kg/hr infusion</td></tr>
                            <tr><td>ACS/PCI</td><td>60 units/kg bolus (max 4000), 12 units/kg/hr (max 1000)</td></tr>
                            <tr><td>DVT prophylaxis</td><td>5000 units SubQ q8-12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>aPTT:</strong> Target 1.5-2.5√ó control (typically 60-80 sec) - check q6h until stable</li>
                            <li><strong>Anti-Xa:</strong> Target 0.3-0.7 units/mL (more reliable in some patients)</li>
                            <li><strong>Platelets:</strong> Check baseline and day 4 for HIT screening</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Bleeding</strong> - most common</li>
                            <li><strong>HIT (Heparin-Induced Thrombocytopenia):</strong> Type II - immune-mediated, occurs days 5-14, paradoxical thrombosis</li>
                            <li>Osteoporosis (prolonged use)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Protamine sulfate:</strong> 1 mg per 100 units heparin (max 50 mg). Reduce dose if heparin given >30 min ago.</p>
                    </div>
                </div>
                <div class="warning-box">HIT: If platelets drop >50% or to <150K on days 5-14, calculate 4Ts score. Stop ALL heparin (including flushes) and start alternative anticoagulant (argatroban, bivalirudin).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="im_guidev3B20.html#acs" class="guide-link">IMCRG: ACS</a>
                </div>
            </div>
        </div>

        <!-- ENOXAPARIN -->
        <div class="drug-card" data-search="enoxaparin lovenox lmwh low molecular weight heparin dvt pe prophylaxis treatment">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Enoxaparin</span>
                <span class="drug-brand">(Lovenox)</span>
                <span class="drug-class-badge">LMWH</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Low molecular weight heparin; primarily anti-Xa activity (3:1 ratio anti-Xa:anti-IIa). More predictable pharmacokinetics than UFH.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>VTE prophylaxis (medical/surgical patients)</li>
                            <li>VTE treatment</li>
                            <li>ACS/NSTEMI</li>
                            <li>Bridge therapy</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>DVT prophylaxis</td><td>40 mg SubQ daily OR 30 mg SubQ q12h (high-risk)</td></tr>
                            <tr><td>VTE treatment</td><td>1 mg/kg SubQ q12h OR 1.5 mg/kg SubQ daily</td></tr>
                            <tr><td>ACS/NSTEMI</td><td>1 mg/kg SubQ q12h</td></tr>
                            <tr><td>CrCl <30</td><td>Prophylaxis: 30 mg daily; Treatment: 1 mg/kg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Routine monitoring NOT required (predictable PK)</li>
                            <li><strong>Check anti-Xa levels if:</strong> Obesity, renal impairment, pregnancy, extremes of weight</li>
                            <li>Target anti-Xa (peak, 4h post-dose): 0.6-1.0 units/mL (q12h dosing); 1.0-2.0 (daily dosing)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Reversal</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Bleeding, injection site reactions, HIT (lower risk than UFH)</li>
                            <li><strong>Partial reversal:</strong> Protamine 1 mg per 1 mg enoxaparin (within 8h) - only ~60% reversal</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Avoid enoxaparin in severe renal impairment (CrCl <30) if possible - accumulates. If must use, reduce dose and consider anti-Xa monitoring.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="nephrology_study_guide1.html#drugs" class="guide-link">Nephro: Drug Dosing</a>
                </div>
            </div>
        </div>

        <!-- WARFARIN -->
        <div class="drug-card" data-search="warfarin coumadin vitamin k antagonist inr afib mechanical valve dvt pe">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Warfarin</span>
                <span class="drug-brand">(Coumadin)</span>
                <span class="drug-class-badge">Vitamin K Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits vitamin K epoxide reductase ‚Üí blocks synthesis of factors II, VII, IX, X, protein C, protein S. Delayed onset (3-5 days for full effect).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Mechanical heart valves</strong> (DOACs contraindicated)</li>
                            <li>Antiphospholipid syndrome with thrombosis</li>
                            <li>AF, VTE (when DOACs not appropriate)</li>
                            <li>LV thrombus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing & Targets</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>INR Target</th></tr>
                            <tr><td>AF, VTE, bioprosthetic valve</td><td>2.0-3.0</td></tr>
                            <tr><td>Mechanical mitral valve</td><td>2.5-3.5</td></tr>
                            <tr><td>Mechanical aortic valve (newer)</td><td>2.0-3.0</td></tr>
                        </table>
                        <p>Start 5 mg daily; adjust based on INR (check day 3-4, then q2-3 days until stable)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Interactions & Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>MANY drug interactions</strong> - check every new medication</li>
                            <li>Increase INR: Amiodarone, TMP-SMX, metronidazole, fluconazole, statins</li>
                            <li>Decrease INR: Rifampin, carbamazepine, phenytoin, vitamin K</li>
                            <li>Bleeding, skin necrosis (protein C deficiency), teratogenic</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Reversal</th></tr>
                            <tr><td>Supratherapeutic, no bleeding</td><td>Hold warfarin, ¬± vitamin K 1-2.5mg PO</td></tr>
                            <tr><td>INR >10, no bleeding</td><td>Hold + vitamin K 2.5-5mg PO</td></tr>
                            <tr><td>Serious bleeding</td><td>Hold + 4-factor PCC + vitamin K 10mg IV</td></tr>
                            <tr><td>Life-threatening</td><td>4-factor PCC (25-50 units/kg) + vitamin K 10mg IV</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Warfarin initially causes transient hypercoagulable state (protein C/S deplete faster than clotting factors) - always bridge with heparin for 5 days AND until INR therapeutic √ó2.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="rheumatology_study_guide4.html#aps" class="guide-link">Rheum: APS</a>
                </div>
            </div>
        </div>

        <!-- APIXABAN -->
        <div class="drug-card" data-search="apixaban eliquis doac noac factor xa afib dvt pe stroke">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Apixaban</span>
                <span class="drug-brand">(Eliquis)</span>
                <span class="drug-class-badge">Direct Xa Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct factor Xa inhibitor. Does not require antithrombin. Predictable PK - no routine monitoring needed.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nonvalvular AF stroke prevention</li>
                            <li>VTE treatment and prevention</li>
                            <li>VTE prophylaxis (hip/knee replacement)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (standard)</td><td>5 mg PO BID</td></tr>
                            <tr><td>AF (dose reduction*)</td><td>2.5 mg PO BID</td></tr>
                            <tr><td>VTE treatment</td><td>10 mg BID √ó 7 days, then 5 mg BID</td></tr>
                            <tr><td>VTE extended prevention</td><td>2.5 mg PO BID</td></tr>
                            <tr><td>DVT prophylaxis (joint)</td><td>2.5 mg PO BID</td></tr>
                        </table>
                        <p>*Reduce to 2.5 mg BID if ‚â•2 of: age ‚â•80, weight ‚â§60 kg, Cr ‚â•1.5</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Best safety profile</strong> among DOACs (lowest bleeding in ARISTOTLE)</li>
                            <li>Can use in moderate renal impairment (with dose adjustment)</li>
                            <li>Avoid with strong dual CYP3A4/P-gp inhibitors (ketoconazole, ritonavir)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Andexanet alfa (Andexxa):</strong> Specific reversal agent for factor Xa inhibitors</p>
                        <p><strong>4-factor PCC:</strong> If andexanet unavailable</p>
                    </div>
                </div>
                <div class="pearl-box">Apixaban has the best safety data among DOACs - lowest rates of major bleeding in trials. Preferred in elderly and patients with renal impairment (can use down to CrCl 15-25).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                </div>
            </div>
        </div>

        <!-- RIVAROXABAN -->
        <div class="drug-card" data-search="rivaroxaban xarelto doac noac factor xa afib dvt pe once daily">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Rivaroxaban</span>
                <span class="drug-brand">(Xarelto)</span>
                <span class="drug-class-badge">Direct Xa Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications & Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (CrCl >50)</td><td>20 mg PO daily with food</td></tr>
                            <tr><td>AF (CrCl 15-50)</td><td>15 mg PO daily with food</td></tr>
                            <tr><td>VTE treatment</td><td>15 mg BID √ó 21 days, then 20 mg daily</td></tr>
                            <tr><td>VTE extended</td><td>10 mg PO daily</td></tr>
                            <tr><td>CAD/PAD</td><td>2.5 mg PO BID (with aspirin)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>MUST take with food</strong> for adequate absorption (15 mg and 20 mg doses)</li>
                            <li>Once-daily dosing (advantage for adherence)</li>
                            <li>Higher GI bleeding risk vs apixaban</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Rivaroxaban 15 mg and 20 mg doses MUST be taken with food - absorption reduced by 30-40% if taken fasting.</div>
            </div>
        </div>

        <!-- DABIGATRAN -->
        <div class="drug-card" data-search="dabigatran pradaxa doac noac thrombin inhibitor afib idarucizumab">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dabigatran</span>
                <span class="drug-brand">(Pradaxa)</span>
                <span class="drug-class-badge">Direct Thrombin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct thrombin (factor IIa) inhibitor. Only oral DTI available.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (CrCl >30)</td><td>150 mg PO BID</td></tr>
                            <tr><td>AF (CrCl 15-30)</td><td>75 mg PO BID</td></tr>
                            <tr><td>VTE treatment</td><td>150 mg BID after 5-10 days parenteral</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Higher dyspepsia/GI upset rate</li>
                            <li>Store in original container (moisture-sensitive)</li>
                            <li>Most renally dependent DOAC - avoid if CrCl <15</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Idarucizumab (Praxbind):</strong> Specific reversal agent - 5g IV (given as 2 √ó 2.5g)</p>
                    </div>
                </div>
                <div class="pearl-box">Dabigatran is the only DOAC with a specific, fully effective reversal agent (idarucizumab). Consider for patients at high bleeding risk who may need emergent reversal.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= CARDIAC - VASOPRESSORS ======================= -->
<div class="drug-category" id="cardiac-vasopressors">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ù§Ô∏è Vasopressors & Inotropes</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- NOREPINEPHRINE -->
        <div class="drug-card" data-search="norepinephrine levophed vasopressor septic shock alpha adrenergic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Norepinephrine</span>
                <span class="drug-brand">(Levophed)</span>
                <span class="drug-class-badge">Œ±1 > Œ≤1 Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Potent Œ±1-adrenergic agonist (vasoconstriction) with mild Œ≤1 activity (inotropy). First-line vasopressor for most shock states.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Septic shock:</strong> First-line vasopressor</li>
                            <li>Distributive shock</li>
                            <li>Cardiogenic shock (with inotrope)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 0.1-0.5 mcg/kg/min</p>
                        <p><strong>Titrate:</strong> 0.1-0.3 mcg/kg/min increments q5-15 min</p>
                        <p><strong>Typical range:</strong> 0.1-2 mcg/kg/min (can go higher in refractory shock)</p>
                        <p><strong>Target:</strong> MAP ‚â•65 mmHg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Peripheral ischemia (digits, limbs)</li>
                            <li>Arrhythmias</li>
                            <li>Tissue necrosis with extravasation</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Extravasation causes severe tissue necrosis. Use central line when possible. If peripheral, use large vein, monitor closely, and treat extravasation with phentolamine.</div>
                <div class="pearl-box">Norepinephrine is first-line for septic shock per Surviving Sepsis Campaign. Superior to dopamine (less arrhythmia, lower mortality in some analyses).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="nephrology_study_guide1.html#hrs" class="guide-link">Nephro: HRS</a>
                </div>
            </div>
        </div>

        <!-- VASOPRESSIN -->
        <div class="drug-card" data-search="vasopressin pitressin v1 receptor septic shock catecholamine sparing">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Vasopressin</span>
                <span class="drug-brand">(Pitressin)</span>
                <span class="drug-class-badge">V1 Receptor Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">V1 receptor agonist ‚Üí vascular smooth muscle contraction. Non-adrenergic mechanism (works when catecholamine receptors downregulated).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Septic shock (add to norepinephrine if MAP not at goal)</li>
                            <li>Catecholamine-sparing strategy</li>
                            <li>Variceal bleeding (alternative to octreotide)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Septic shock:</strong> 0.03-0.04 units/min (fixed dose, no titration)</p>
                        <p><strong>Variceal bleeding:</strong> 0.2-0.4 units/min</p>
                    </div>
                </div>
                <div class="pearl-box">Vasopressin is used at FIXED dose (0.03-0.04 units/min) in septic shock - not titrated. Add when norepinephrine dose is escalating to reduce catecholamine requirements.</div>
            </div>
        </div>

        <!-- DOBUTAMINE -->
        <div class="drug-card" data-search="dobutamine inotrope beta1 cardiogenic shock heart failure low output">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dobutamine</span>
                <span class="drug-brand">(Dobutrex)</span>
                <span class="drug-class-badge">Œ≤1 Agonist (Inotrope)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤1 agonist ‚Üí increased contractility and cardiac output. Mild Œ≤2 effect ‚Üí may cause vasodilation and hypotension.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Cardiogenic shock:</strong> Low cardiac output with adequate BP</li>
                            <li>Severe heart failure with hypoperfusion</li>
                            <li>Inotropic support post-cardiac surgery</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 2.5-5 mcg/kg/min</p>
                        <p><strong>Titrate:</strong> Up to 20 mcg/kg/min</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>May cause hypotension (Œ≤2 vasodilation) - often combined with vasopressor</li>
                            <li>Arrhythmogenic</li>
                            <li>Avoid in severe aortic stenosis</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Dobutamine is an INOTROPE (increases contractility) not a vasopressor. It may DROP blood pressure due to Œ≤2 vasodilation. Often used with norepinephrine in cardiogenic shock.</div>
            </div>
        </div>

        <!-- EPINEPHRINE -->
        <div class="drug-card" data-search="epinephrine adrenaline cardiac arrest anaphylaxis alpha beta agonist">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Epinephrine</span>
                <span class="drug-brand">(Adrenalin)</span>
                <span class="drug-class-badge">Œ± + Œ≤ Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ±1, Œ≤1, Œ≤2 agonist. Dose-dependent effects: low dose ‚Üí Œ≤ predominant (inotropy, bronchodilation); high dose ‚Üí Œ± predominant (vasoconstriction).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Cardiac arrest</td><td>1 mg IV push q3-5 min</td></tr>
                            <tr><td>Anaphylaxis</td><td>0.3-0.5 mg IM (1:1000) - repeat q5-15 min PRN</td></tr>
                            <tr><td>Shock (infusion)</td><td>0.01-0.5 mcg/kg/min</td></tr>
                            <tr><td>Bradycardia (infusion)</td><td>2-10 mcg/min</td></tr>
                        </table>
                    </div>
                </div>
                <div class="warning-box">Anaphylaxis: IM epinephrine (0.3-0.5 mg of 1:1000) into lateral thigh is first-line. Do NOT delay. IV epinephrine only for refractory cases with careful titration.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#anaphylaxis" class="guide-link">IMCRG: Anaphylaxis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIFUNGALS ======================= -->
<div class="drug-category" id="antifungals">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üçÑ Antifungals</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- FLUCONAZOLE -->
        <div class="drug-card" data-search="fluconazole diflucan azole candida cryptococcus cyp450 qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Fluconazole</span>
                <span class="drug-brand">(Diflucan)</span>
                <span class="drug-class-badge">Triazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits lanosterol 14-Œ±-demethylase (CYP51) ‚Üí blocks ergosterol synthesis ‚Üí fungal membrane disruption. Fungistatic.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Candida:</strong> C. albicans, C. parapsilosis, C. tropicalis</li>
                            <li><strong>NOT active:</strong> C. krusei (intrinsic resistance), C. glabrata (often resistant)</li>
                            <li><strong>Cryptococcus:</strong> Maintenance therapy</li>
                            <li><strong>Key uses:</strong> Candidiasis (oropharyngeal, esophageal, vulvovaginal, candidemia), cryptococcal meningitis (consolidation/maintenance)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Oropharyngeal candidiasis</td><td>200 mg day 1, then 100-200 mg daily √ó 7-14 days</td></tr>
                            <tr><td>Esophageal candidiasis</td><td>200-400 mg daily √ó 14-21 days</td></tr>
                            <tr><td>Candidemia</td><td>800 mg load, then 400 mg daily (12 mg/kg load, 6 mg/kg daily)</td></tr>
                            <tr><td>Cryptococcal maintenance</td><td>200 mg daily √ó ‚â•1 year</td></tr>
                            <tr><td>VVC (single dose)</td><td>150 mg PO √ó 1</td></tr>
                        </table>
                        <p><strong>Renal:</strong> Reduce dose 50% if CrCl &lt;50</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Interactions</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>QTc prolongation</li>
                            <li>Hepatotoxicity (monitor LFTs)</li>
                            <li><strong>CYP2C9, 2C19, 3A4 inhibitor:</strong> Many drug interactions (warfarin, phenytoin, cyclosporine, tacrolimus)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Fluconazole has excellent oral bioavailability (~90%) and CSF penetration. First-line for susceptible Candida, but always check species - C. glabrata and C. krusei are often resistant.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#candidemia" class="guide-link">IMCRG: Candidemia</a>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

        <!-- MICAFUNGIN -->
        <div class="drug-card" data-search="micafungin mycamine echinocandin candida aspergillus beta glucan">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Micafungin</span>
                <span class="drug-brand">(Mycamine)</span>
                <span class="drug-class-badge">Echinocandin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits Œ≤-(1,3)-D-glucan synthase ‚Üí disrupts fungal cell wall. Fungicidal against Candida, fungistatic against Aspergillus.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Candida:</strong> ALL species including C. glabrata, C. krusei (fluconazole-resistant)</li>
                            <li><strong>Aspergillus:</strong> Salvage therapy</li>
                            <li><strong>NOT active:</strong> Cryptococcus, mucormycosis, endemic fungi</li>
                            <li><strong>Key uses:</strong> Candidemia (first-line for severe/unstable), esophageal candidiasis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Candidemia</td><td>100 mg IV daily</td></tr>
                            <tr><td>Esophageal candidiasis</td><td>150 mg IV daily</td></tr>
                            <tr><td>Prophylaxis (HSCT)</td><td>50 mg IV daily</td></tr>
                        </table>
                        <p>No renal or hepatic adjustment needed</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Excellent safety profile</li>
                            <li>Few drug interactions</li>
                            <li>IV only (no oral formulation)</li>
                            <li>Poor CNS penetration - NOT for CNS infections</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Echinocandins (micafungin, caspofungin, anidulafungin) are first-line for severe/critically ill patients with candidemia - broader spectrum than fluconazole and fungicidal.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

        <!-- VORICONAZOLE -->
        <div class="drug-card" data-search="voriconazole vfend azole aspergillus invasive visual photosensitivity">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Voriconazole</span>
                <span class="drug-brand">(Vfend)</span>
                <span class="drug-class-badge">Triazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>First-line for invasive aspergillosis</strong></li>
                            <li>Broad Candida coverage (including C. krusei)</li>
                            <li>Some activity against endemic fungi, Fusarium, Scedosporium</li>
                            <li>NOT active: Mucormycosis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Loading</th><th>Maintenance</th></tr>
                            <tr><td>IV</td><td>6 mg/kg q12h √ó 2 doses</td><td>4 mg/kg q12h</td></tr>
                            <tr><td>PO (>40 kg)</td><td>400 mg q12h √ó 2 doses</td><td>200 mg q12h</td></tr>
                        </table>
                        <p><strong>Target trough:</strong> 1-5 mcg/mL (monitor weekly)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Visual disturbances</strong> (30%) - transient, reversible</li>
                            <li><strong>Photosensitivity</strong> - sunscreen essential, risk of skin cancer with prolonged use</li>
                            <li>Hepatotoxicity (monitor LFTs)</li>
                            <li>QTc prolongation</li>
                            <li>Many drug interactions (CYP450)</li>
                            <li>Fluorosis (prolonged therapy)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Voriconazole levels are highly variable - therapeutic drug monitoring (TDM) is essential. Target trough 1-5 mcg/mL. Toxicity increases with levels >5.5.</div>
                <div class="pearl-box">Voriconazole is first-line for invasive aspergillosis. Visual side effects ("seeing in technicolor") are common but transient - warn patients.</div>
            </div>
        </div>

        <!-- AMPHOTERICIN B -->
        <div class="drug-card" data-search="amphotericin ambisome liposomal polyene nephrotoxic mucormycosis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amphotericin B Liposomal</span>
                <span class="drug-brand">(AmBisome)</span>
                <span class="drug-class-badge">Polyene</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds ergosterol ‚Üí creates membrane pores ‚Üí fungal cell death. Broadest spectrum antifungal.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Broadest antifungal spectrum:</strong> Candida, Aspergillus, Cryptococcus, endemic fungi, Mucormycosis</li>
                            <li><strong>Key uses:</strong> Mucormycosis (first-line), cryptococcal meningitis (induction), severe/refractory fungal infections</li>
                            <li>NOT active: C. lusitaniae, some Aspergillus terreus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3-5 mg/kg IV daily</td></tr>
                            <tr><td>Mucormycosis</td><td>5-10 mg/kg IV daily</td></tr>
                            <tr><td>Cryptococcal meningitis</td><td>3-4 mg/kg IV daily + flucytosine √ó 2 weeks</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Nephrotoxicity:</strong> Less with liposomal than conventional (still monitor Cr, K, Mg daily)</li>
                            <li>Infusion reactions (fever, rigors - premedicate)</li>
                            <li>Hypokalemia, hypomagnesemia</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Amphotericin causes renal tubular toxicity - aggressively replace K+ and Mg2+. Consider NS bolus before infusion to reduce nephrotoxicity.</div>
                <div class="pearl-box">ONLY use liposomal amphotericin (AmBisome) - conventional amphotericin has unacceptable nephrotoxicity. Liposomal is first-line for mucormycosis (only antifungal with reliable activity).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro: Nephrotoxins</a>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= CORTICOSTEROIDS ======================= -->
<div class="drug-category" id="corticosteroids">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíâ Corticosteroids</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- PREDNISONE -->
        <div class="drug-card" data-search="prednisone glucocorticoid anti-inflammatory immunosuppressive taper">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Prednisone</span>
                <span class="drug-brand">(Deltasone)</span>
                <span class="drug-class-badge">Glucocorticoid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds glucocorticoid receptor ‚Üí translocates to nucleus ‚Üí modulates gene transcription. Anti-inflammatory and immunosuppressive. Prodrug (converted to prednisolone in liver).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>COPD/asthma exacerbation</li>
                            <li>Autoimmune diseases (RA, SLE, vasculitis, IBD)</li>
                            <li>Allergic reactions</li>
                            <li>Adrenal insufficiency replacement</li>
                            <li>Transplant rejection</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>COPD exacerbation</td><td>40 mg PO daily √ó 5 days</td></tr>
                            <tr><td>Asthma exacerbation</td><td>40-60 mg PO daily √ó 5-7 days</td></tr>
                            <tr><td>Anti-inflammatory</td><td>0.5-1 mg/kg/day</td></tr>
                            <tr><td>High-dose immunosuppression</td><td>1-2 mg/kg/day</td></tr>
                            <tr><td>GCA/PMR</td><td>40-60 mg daily (GCA) or 15-20 mg daily (PMR)</td></tr>
                        </table>
                        <p><strong>Relative potency:</strong> Prednisone 5 mg = Hydrocortisone 20 mg = Dexamethasone 0.75 mg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Metabolic:</strong> Hyperglycemia, weight gain, cushingoid features</li>
                            <li><strong>Bone:</strong> Osteoporosis, avascular necrosis</li>
                            <li><strong>Infection:</strong> Increased susceptibility, masks fever</li>
                            <li><strong>Psychiatric:</strong> Insomnia, mood changes, psychosis</li>
                            <li><strong>GI:</strong> Peptic ulcer (with NSAIDs), pancreatitis</li>
                            <li><strong>Adrenal:</strong> HPA axis suppression (taper if >3 weeks)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Taper required if used >3 weeks or high doses - HPA axis suppression can cause adrenal crisis if stopped abruptly. PCP prophylaxis if prednisone ‚â•20 mg/day for ‚â•1 month.</div>
                <div class="pearl-box">Short courses (‚â§5 days) can be stopped without taper. For longer courses, typical taper: reduce by 10-20% every 1-2 weeks or 5-10 mg per week.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#copd" class="guide-link">IMCRG: COPD</a>
                    <a href="rheumatology_study_guide4.html" class="guide-link">Rheum Guide</a>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                </div>
            </div>
        </div>

        <!-- DEXAMETHASONE -->
        <div class="drug-card" data-search="dexamethasone decadron glucocorticoid long-acting cerebral edema covid meningitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dexamethasone</span>
                <span class="drug-brand">(Decadron)</span>
                <span class="drug-class-badge">Glucocorticoid (Long-Acting)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Most potent glucocorticoid (7√ó prednisone)</li>
                            <li>Longest half-life (36-54 hr)</li>
                            <li>Minimal mineralocorticoid activity (no salt/water retention)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Bacterial meningitis</td><td>0.15 mg/kg q6h √ó 4 days (give BEFORE or with first abx dose)</td></tr>
                            <tr><td>Cerebral edema (tumor/mets)</td><td>10 mg IV load, then 4 mg q6h</td></tr>
                            <tr><td>COVID-19 (hypoxic)</td><td>6 mg IV/PO daily √ó 10 days</td></tr>
                            <tr><td>Spinal cord compression</td><td>10-100 mg IV load, then high-dose maintenance</td></tr>
                            <tr><td>Croup</td><td>0.6 mg/kg PO √ó 1</td></tr>
                            <tr><td>Nausea (chemo)</td><td>8-20 mg IV/PO</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Dexamethasone for bacterial meningitis: Give 15-20 min BEFORE first antibiotic dose - reduces hearing loss and mortality in pneumococcal meningitis.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                    <a href="rheumatology_study_guide4.html" class="guide-link">Rheum Guide</a>
                </div>
            </div>
        </div>

        <!-- HYDROCORTISONE -->
        <div class="drug-card" data-search="hydrocortisone solu-cortef adrenal insufficiency septic shock stress dose mineralocorticoid">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Hydrocortisone</span>
                <span class="drug-brand">(Solu-Cortef)</span>
                <span class="drug-class-badge">Glucocorticoid + Mineralocorticoid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Physiologic glucocorticoid (cortisol)</li>
                            <li>Has mineralocorticoid activity (sodium retention)</li>
                            <li>Short half-life (8-12 hr)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Adrenal crisis</td><td>100 mg IV bolus, then 50-100 mg q8h or continuous infusion</td></tr>
                            <tr><td>Septic shock (refractory)</td><td>50 mg IV q6h or 200 mg/day continuous √ó 7 days</td></tr>
                            <tr><td>Stress dosing (major surgery)</td><td>50-100 mg IV q8h √ó 1-3 days</td></tr>
                            <tr><td>Physiologic replacement</td><td>15-25 mg PO daily (in divided doses)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Hydrocortisone is preferred for adrenal insufficiency because it provides both glucocorticoid and mineralocorticoid activity. In septic shock, use for refractory hypotension on escalating vasopressors.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#adrenal" class="guide-link">IMCRG: Adrenal Crisis</a>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= CARDIAC - ANTIHYPERTENSIVES ======================= -->
<div class="drug-category" id="cardiac-antihypertensives">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ù§Ô∏è Antihypertensives</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- LISINOPRIL -->
        <div class="drug-card" data-search="lisinopril ace inhibitor acei hypertension heart failure diabetic nephropathy cough angioedema">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Lisinopril</span>
                <span class="drug-brand">(Prinivil, Zestril)</span>
                <span class="drug-class-badge">ACE Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits angiotensin-converting enzyme ‚Üí blocks conversion of angiotensin I to II ‚Üí vasodilation, decreased aldosterone, reduced cardiac remodeling.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypertension (first-line)</li>
                            <li>HFrEF (mortality benefit)</li>
                            <li>Post-MI (LV dysfunction)</li>
                            <li>Diabetic nephropathy (proteinuria reduction)</li>
                            <li>CKD with proteinuria</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>HTN</td><td>10 mg daily</td><td>20-40 mg daily</td></tr>
                            <tr><td>HFrEF</td><td>2.5-5 mg daily</td><td>20-40 mg daily</td></tr>
                            <tr><td>Post-MI</td><td>5 mg daily</td><td>10 mg daily</td></tr>
                        </table>
                        <p><strong>CrCl 10-30:</strong> Start 2.5-5 mg daily</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Dry cough</strong> (10-20%) - bradykinin accumulation; switch to ARB if intolerable</li>
                            <li><strong>Angioedema</strong> (0.1-0.5%) - more common in Black patients; STOP permanently</li>
                            <li>Hyperkalemia</li>
                            <li>Acute kidney injury (especially with volume depletion, NSAIDs, bilateral RAS)</li>
                            <li>Hypotension (especially first dose in HF)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Contraindicated in pregnancy - fetal toxicity (renal dysgenesis, oligohydramnios, skull hypoplasia). Discontinue immediately if pregnancy detected.</div>
                <div class="warning-box">Check Cr and K+ 1-2 weeks after initiation or dose increase. Up to 30% rise in Cr acceptable if stable. Stop if >30% rise or hyperkalemia develops.</div>
                <div class="pearl-box">ACEi provide mortality benefit in HFrEF independent of BP lowering. Titrate to target doses used in trials (not just until BP controlled).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="nephrology_study_guide1.html#htn" class="guide-link">Nephro: HTN</a>
                </div>
            </div>
        </div>

        <!-- LOSARTAN -->
        <div class="drug-card" data-search="losartan arb angiotensin receptor blocker hypertension heart failure diabetic nephropathy">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Losartan</span>
                <span class="drug-brand">(Cozaar)</span>
                <span class="drug-class-badge">ARB</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Blocks angiotensin II type 1 (AT1) receptor ‚Üí similar effects to ACEi but does NOT affect bradykinin (no cough).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Same as ACEi - use when ACEi not tolerated (cough)</li>
                            <li>Hypertension, HFrEF, diabetic nephropathy</li>
                            <li>Stroke prevention in HTN with LVH</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>HTN:</strong> 25-50 mg daily, max 100 mg daily</p>
                        <p><strong>HFrEF:</strong> Start 25 mg daily, target 150 mg daily</p>
                        <p>Also has uricosuric effect (lowers uric acid)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar to ACEi EXCEPT: No cough (no bradykinin effect)</li>
                            <li>Angioedema - less common but still possible</li>
                            <li>Hyperkalemia, AKI</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">ARBs are NOT cough-free for ACEi angioedema - still ~10% cross-reactivity. For ACEi angioedema, consider ARB only if ACEi essential, with close monitoring.</div>
            </div>
        </div>

        <!-- AMLODIPINE -->
        <div class="drug-card" data-search="amlodipine norvasc calcium channel blocker ccb dihydropyridine hypertension angina edema">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amlodipine</span>
                <span class="drug-brand">(Norvasc)</span>
                <span class="drug-class-badge">DHP CCB</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Blocks L-type calcium channels in vascular smooth muscle ‚Üí vasodilation. Dihydropyridine (DHP) = primarily vascular effects (vs non-DHP which affect heart).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypertension (first-line, especially Black patients, elderly)</li>
                            <li>Stable angina</li>
                            <li>Vasospastic (Prinzmetal) angina</li>
                            <li>Raynaud phenomenon</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>HTN:</strong> 2.5-5 mg daily, max 10 mg daily</p>
                        <p><strong>Angina:</strong> 5-10 mg daily</p>
                        <p>Long half-life (30-50 hr) - once daily dosing, takes 7-8 days to reach steady state</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Peripheral edema</strong> (dose-dependent, up to 10%) - NOT fluid overload; due to arteriolar dilation</li>
                            <li>Flushing, headache</li>
                            <li>Gingival hyperplasia</li>
                            <li>Reflex tachycardia (less than other DHPs)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Amlodipine edema is NOT responsive to diuretics - it's redistribution, not volume overload. Adding ACEi/ARB may help by dilating venous side.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#htn" class="guide-link">Nephro: HTN</a>
                    <a href="rheumatology_study_guide4.html#raynauds" class="guide-link">Rheum: Raynaud's</a>
                </div>
            </div>
        </div>

        <!-- METOPROLOL -->
        <div class="drug-card" data-search="metoprolol lopressor toprol beta blocker hypertension heart failure afib rate control">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Metoprolol</span>
                <span class="drug-brand">(Lopressor, Toprol-XL)</span>
                <span class="drug-class-badge">Œ≤1-Selective Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Selective Œ≤1-adrenergic antagonist ‚Üí decreases HR, contractility, AV conduction, and renin release. Cardioselective at low doses.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypertension</li>
                            <li>HFrEF (metoprolol succinate - mortality benefit)</li>
                            <li>Rate control (AFib, AFL)</li>
                            <li>Post-MI (secondary prevention)</li>
                            <li>Angina</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Indication</th><th>Dose</th></tr>
                            <tr><td rowspan="2">Tartrate (Lopressor)</td><td>HTN</td><td>25-100 mg PO BID</td></tr>
                            <tr><td>Acute rate control</td><td>5 mg IV q5min √ó 3 PRN</td></tr>
                            <tr><td rowspan="2">Succinate (Toprol-XL)</td><td>HTN</td><td>25-100 mg PO daily</td></tr>
                            <tr><td>HFrEF</td><td>Start 12.5-25 mg daily, target 200 mg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Bradycardia, heart block</li>
                            <li>Fatigue, depression, sexual dysfunction</li>
                            <li>Bronchospasm (less with Œ≤1-selective, but still caution in asthma)</li>
                            <li>Masks hypoglycemia symptoms</li>
                            <li><strong>Avoid in:</strong> Decompensated HF, severe bradycardia, 2nd/3rd degree AV block, severe asthma</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Do NOT stop beta-blockers abruptly - rebound tachycardia, hypertension, angina. Taper over 1-2 weeks.</div>
                <div class="pearl-box">For HFrEF: Only metoprolol SUCCINATE (Toprol-XL) has mortality data - NOT tartrate. Start low and titrate slowly ("start low, go slow").</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                </div>
            </div>
        </div>

        <!-- CARVEDILOL -->
        <div class="drug-card" data-search="carvedilol coreg beta blocker alpha blocker heart failure hypertension">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Carvedilol</span>
                <span class="drug-brand">(Coreg)</span>
                <span class="drug-class-badge">Œ±/Œ≤ Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-selective Œ≤-blocker (Œ≤1 and Œ≤2) PLUS Œ±1-blocker ‚Üí vasodilation in addition to Œ≤-blockade. Also has antioxidant properties.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>HFrEF (mortality benefit)</li>
                            <li>Hypertension</li>
                            <li>Post-MI with LV dysfunction</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>HFrEF</td><td>3.125 mg BID</td><td>25 mg BID (50 mg BID if >85 kg)</td></tr>
                            <tr><td>HTN</td><td>6.25 mg BID</td><td>25 mg BID</td></tr>
                        </table>
                        <p>Take with food to slow absorption and reduce orthostatic hypotension</p>
                    </div>
                </div>
                <div class="pearl-box">Carvedilol has Œ±-blocking (vasodilating) effect - may cause more orthostatic hypotension than metoprolol. Take with food. Both have equal mortality benefit in HFrEF.</div>
            </div>
        </div>

        <!-- LABETALOL -->
        <div class="drug-card" data-search="labetalol trandate alpha beta blocker hypertensive emergency pregnancy safe">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Labetalol</span>
                <span class="drug-brand">(Trandate)</span>
                <span class="drug-class-badge">Œ±/Œ≤ Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ±1 and non-selective Œ≤-blocker (Œ≤:Œ± ratio ~7:1 IV, ~3:1 PO). Reduces SVR without reflex tachycardia.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypertensive emergency</strong> (first-line for most)</li>
                            <li><strong>Pregnancy-related HTN</strong> (preeclampsia, eclampsia)</li>
                            <li>Aortic dissection (with esmolol)</li>
                            <li>Perioperative hypertension</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>IV bolus</td><td>20 mg, then 40-80 mg q10min PRN (max 300 mg total)</td></tr>
                            <tr><td>IV infusion</td><td>0.5-2 mg/min</td></tr>
                            <tr><td>PO</td><td>100-400 mg BID</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Labetalol is preferred for hypertensive emergencies in pregnancy (preeclampsia/eclampsia). Also first-line for most other HTN emergencies.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#htn-emergency" class="guide-link">IMCRG: HTN Emergency</a>
                    <a href="nephrology_study_guide1.html#htnemergency" class="guide-link">Nephro: HTN Emergency</a>
                </div>
            </div>
        </div>

        <!-- HYDRALAZINE -->
        <div class="drug-card" data-search="hydralazine apresoline vasodilator heart failure pregnancy lupus-like">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Hydralazine</span>
                <span class="drug-brand">(Apresoline)</span>
                <span class="drug-class-badge">Direct Vasodilator</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct arteriolar vasodilation (mechanism not fully understood - may involve NO). Does NOT dilate veins.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>HFrEF (with isosorbide dinitrate - mortality benefit in Black patients: A-HeFT trial)</li>
                            <li>Hypertension (adjunctive)</li>
                            <li>Pregnancy HTN (alternative to labetalol)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>HFrEF (with nitrate)</td><td>25-100 mg PO TID (BiDil = 37.5/20 mg combo)</td></tr>
                            <tr><td>HTN (acute)</td><td>10-20 mg IV q4-6h PRN</td></tr>
                            <tr><td>HTN (chronic)</td><td>25-100 mg PO BID-QID</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Reflex tachycardia (use with Œ≤-blocker)</li>
                            <li><strong>Drug-induced lupus</strong> (especially with doses >200 mg/day, slow acetylators)</li>
                            <li>Headache, flushing, palpitations</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Drug-induced lupus: ANA+, anti-histone antibodies+. Presents with arthralgias, serositis, rash. Resolves with discontinuation.</div>
                <div class="pearl-box">Hydralazine + isosorbide dinitrate (BiDil) has mortality benefit in Black patients with HFrEF already on ACEi/ARB + Œ≤-blocker (A-HeFT trial).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="rheumatology_study_guide4.html#dil" class="guide-link">Rheum: Drug-Induced Lupus</a>
                </div>
            </div>
        </div>

        <!-- SPIRONOLACTONE -->
        <div class="drug-card" data-search="spironolactone aldactone mra mineralocorticoid antagonist heart failure ascites hyperkalemia gynecomastia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Spironolactone</span>
                <span class="drug-brand">(Aldactone)</span>
                <span class="drug-class-badge">MRA / K+-Sparing Diuretic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Aldosterone receptor antagonist ‚Üí blocks Na+ reabsorption and K+ excretion in collecting duct. Also has anti-androgenic effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>HFrEF (mortality benefit - RALES trial)</li>
                            <li>Cirrhosis with ascites (first-line diuretic)</li>
                            <li>Resistant hypertension</li>
                            <li>Primary hyperaldosteronism</li>
                            <li>Hirsutism, acne (off-label)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>HFrEF</td><td>12.5-25 mg daily (max 50 mg)</td></tr>
                            <tr><td>Ascites</td><td>100 mg daily (max 400 mg); ratio 100:40 with furosemide</td></tr>
                            <tr><td>Resistant HTN</td><td>25-50 mg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hyperkalemia</strong> (especially with ACEi/ARB, renal impairment)</li>
                            <li><strong>Gynecomastia</strong> (anti-androgen effect) - use eplerenone if intolerable</li>
                            <li>Menstrual irregularities</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Monitor K+ closely, especially with ACEi/ARB. Avoid if K+ >5.0 or CrCl <30 mL/min.</div>
                <div class="pearl-box">For cirrhotic ascites: Use spironolactone:furosemide ratio of 100:40 to maintain normokalemia (100 mg spironolactone + 40 mg furosemide).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="im_guidev3B20.html#cirrhosis" class="guide-link">IMCRG: Cirrhosis</a>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                </div>
            </div>
        </div>

        <!-- FUROSEMIDE -->
        <div class="drug-card" data-search="furosemide lasix loop diuretic edema heart failure acute kidney injury">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Furosemide</span>
                <span class="drug-brand">(Lasix)</span>
                <span class="drug-class-badge">Loop Diuretic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits Na-K-2Cl cotransporter (NKCC2) in thick ascending limb ‚Üí blocks 25% of sodium reabsorption. Most potent diuretics.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Acute decompensated heart failure</li>
                            <li>Edema (nephrotic syndrome, cirrhosis)</li>
                            <li>Acute pulmonary edema</li>
                            <li>Hypercalcemia (with saline)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>Acute HF (diuretic naive)</td><td>20-40 mg IV</td></tr>
                            <tr><td>Acute HF (on chronic furosemide)</td><td>IV dose = 1-2.5√ó home PO dose</td></tr>
                            <tr><td>Continuous infusion</td><td>5-20 mg/hr (after bolus)</td></tr>
                            <tr><td>Chronic (PO)</td><td>20-80 mg daily-BID</td></tr>
                        </table>
                        <p><strong>IV:PO ratio ~1:2</strong> (40 mg IV ‚âà 80 mg PO)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Electrolyte depletion:</strong> Hypokalemia, hypomagnesemia, hypocalcemia, hyponatremia</li>
                            <li>Volume depletion, hypotension</li>
                            <li>Ototoxicity (especially with aminoglycosides, rapid IV push)</li>
                            <li>Hyperuricemia, gout</li>
                            <li>Metabolic alkalosis (contraction alkalosis)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">DOSE trial: No difference in outcomes between bolus vs continuous infusion, or low vs high dose strategy. Use what achieves adequate diuresis.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= CARDIAC - ANTIARRHYTHMICS ======================= -->
<div class="drug-category" id="cardiac-antiarrhythmics">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ù§Ô∏è Antiarrhythmics</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- AMIODARONE -->
        <div class="drug-card" data-search="amiodarone pacerone cordarone antiarrhythmic afib vt vf thyroid pulmonary toxicity qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amiodarone</span>
                <span class="drug-brand">(Cordarone, Pacerone)</span>
                <span class="drug-class-badge">Class III Antiarrhythmic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Blocks K+ channels (Class III), but also has Class I (Na+), II (Œ≤-blocking), and IV (Ca2+) effects. Prolongs action potential and refractory period.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Life-threatening ventricular arrhythmias (VT, VF)</li>
                            <li>AF/AFL rate and rhythm control</li>
                            <li>ACLS: Refractory VF/pulseless VT</li>
                            <li>AF in HFrEF (one of few safe options)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Loading</th><th>Maintenance</th></tr>
                            <tr><td>VF/VT (ACLS)</td><td>300 mg IV push</td><td>150 mg IV if needed</td></tr>
                            <tr><td>Stable VT</td><td>150 mg over 10 min</td><td>1 mg/min √ó 6h, then 0.5 mg/min</td></tr>
                            <tr><td>AF (IV)</td><td>150 mg over 10 min</td><td>1 mg/min √ó 6h, then 0.5 mg/min</td></tr>
                            <tr><td>AF (PO loading)</td><td>400-800 mg/day √ó 2-4 weeks</td><td>100-200 mg daily</td></tr>
                        </table>
                        <p>Extremely long half-life (40-55 days) - takes weeks to reach steady state</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Thyroid:</strong> Hypo- or hyperthyroidism (contains iodine) - check TFTs q6 months</li>
                            <li><strong>Pulmonary:</strong> Pulmonary fibrosis (check CXR, PFTs baseline and annually)</li>
                            <li><strong>Hepatic:</strong> Transaminitis, hepatitis (check LFTs q6 months)</li>
                            <li><strong>Cardiac:</strong> QT prolongation, bradycardia, torsades (rare)</li>
                            <li><strong>Other:</strong> Corneal deposits, photosensitivity, blue-gray skin discoloration</li>
                            <li><strong>Drug interactions:</strong> Increases digoxin, warfarin levels (reduce doses by 50%)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Baseline and periodic monitoring required: TFTs, LFTs, CXR, PFTs, ophthalmologic exam. Many drug interactions - check all medications.</div>
                <div class="pearl-box">Amiodarone is one of the few antiarrhythmics safe in HFrEF - most others are contraindicated or proarrhythmic in structural heart disease.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                    <a href="im_guidev3B20.html#vt" class="guide-link">IMCRG: VT</a>
                </div>
            </div>
        </div>

        <!-- DILTIAZEM -->
        <div class="drug-card" data-search="diltiazem cardizem calcium channel blocker rate control afib angina hypertension">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Diltiazem</span>
                <span class="drug-brand">(Cardizem)</span>
                <span class="drug-class-badge">Non-DHP CCB</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-dihydropyridine CCB ‚Üí blocks L-type Ca2+ channels in heart and vessels. Slows AV nodal conduction, reduces HR, and causes vasodilation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>AF/AFL rate control (acute and chronic)</li>
                            <li>SVT (acute termination)</li>
                            <li>Angina (stable, vasospastic)</li>
                            <li>Hypertension</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Indication</th><th>Dose</th></tr>
                            <tr><td rowspan="2">IV</td><td>Acute rate control</td><td>0.25 mg/kg (avg 15-20 mg) over 2 min, may repeat 0.35 mg/kg</td></tr>
                            <tr><td>Infusion</td><td>5-15 mg/hr</td></tr>
                            <tr><td rowspan="2">PO</td><td>Rate control</td><td>120-360 mg daily (extended-release)</td></tr>
                            <tr><td>HTN</td><td>120-540 mg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>HFrEF</strong> - negative inotropy</li>
                            <li>Pre-excited AF (WPW) - may accelerate accessory pathway</li>
                            <li>Severe bradycardia, 2nd/3rd degree AV block</li>
                            <li>Hypotension</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Do NOT use diltiazem or verapamil in HFrEF - negative inotropic effect can precipitate acute decompensation.</div>
                <div class="pearl-box">For AF rate control: Diltiazem preferred over verapamil (less negative inotropy). Do NOT use in WPW with AF - can accelerate conduction down bypass tract ‚Üí VF.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                </div>
            </div>
        </div>

        <!-- DIGOXIN -->
        <div class="drug-card" data-search="digoxin lanoxin digitalis afib heart failure inotrope toxicity yellow vision">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Digoxin</span>
                <span class="drug-brand">(Lanoxin)</span>
                <span class="drug-class-badge">Cardiac Glycoside</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits Na+/K+-ATPase ‚Üí increases intracellular Ca2+ ‚Üí positive inotropy. Also increases vagal tone ‚Üí slows AV conduction (rate control).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>AF rate control (add-on when Œ≤-blocker/CCB insufficient)</li>
                            <li>HFrEF (reduces hospitalizations, no mortality benefit - DIG trial)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Loading</th><th>Maintenance</th></tr>
                            <tr><td>AF (urgent)</td><td>0.5 mg IV, then 0.25 mg q6h √ó 2</td><td>0.125-0.25 mg daily</td></tr>
                            <tr><td>HF (chronic)</td><td>Usually no load</td><td>0.125-0.25 mg daily</td></tr>
                        </table>
                        <p><strong>Target level:</strong> 0.5-1.0 ng/mL (lower targets associated with better outcomes)</p>
                        <p>Renally cleared - reduce dose with CKD</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Toxicity</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Nausea, vomiting, anorexia</li>
                            <li><strong>Visual:</strong> Yellow-green halos, blurred vision</li>
                            <li><strong>Cardiac:</strong> ANY arrhythmia possible - classically bidirectional VT, atrial tachycardia with block, accelerated junctional rhythm</li>
                            <li><strong>CNS:</strong> Confusion, delirium</li>
                        </ul>
                        <p><strong>Risk factors for toxicity:</strong> Hypokalemia, hypomagnesemia, renal impairment, elderly, drug interactions (amiodarone, verapamil, quinidine)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Digoxin immune Fab (DigiFab):</strong> For life-threatening toxicity (K+ >5.5, hemodynamically unstable arrhythmias)</p>
                    </div>
                </div>
                <div class="warning-box">Digoxin toxicity is potentiated by hypokalemia - always check and correct K+ and Mg2+. Toxicity can occur even at "therapeutic" levels.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#digoxin-toxicity" class="guide-link">IMCRG: Digoxin Toxicity</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= DIABETES MEDICATIONS ======================= -->
<div class="drug-category" id="diabetes">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üç¨ Diabetes Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- METFORMIN -->
        <div class="drug-card" data-search="metformin glucophage biguanide type 2 diabetes first line lactic acidosis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Metformin</span>
                <span class="drug-brand">(Glucophage)</span>
                <span class="drug-class-badge">Biguanide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Decreases hepatic gluconeogenesis, increases peripheral insulin sensitivity. Does NOT stimulate insulin secretion ‚Üí no hypoglycemia risk as monotherapy.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>First-line for T2DM</strong> (unless contraindicated)</li>
                            <li>Prediabetes prevention</li>
                            <li>PCOS (off-label)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>Immediate-release</td><td>500 mg BID with meals</td><td>1000 mg BID (max 2550 mg/day)</td></tr>
                            <tr><td>Extended-release</td><td>500 mg daily with dinner</td><td>1500-2000 mg daily</td></tr>
                        </table>
                        <p><strong>Renal dosing:</strong> eGFR 30-45: max 1000 mg/day; eGFR <30: contraindicated</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Nausea, diarrhea, metallic taste (start low, titrate slowly; use ER formulation)</li>
                            <li><strong>Vitamin B12 deficiency</strong> (monitor periodically)</li>
                            <li><strong>Lactic acidosis</strong> (rare but serious - associated with renal impairment, tissue hypoxia)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Hold metformin before and 48h after iodinated contrast if eGFR <60 (check renal function before restarting). Not needed if eGFR >60.</div>
                <div class="pearl-box">Metformin is weight-neutral to weight-losing, has possible CV benefit, and reduces A1c by ~1-1.5%. Only diabetes medication proven to reduce all-cause mortality (UKPDS).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#t2dm" class="guide-link">IMCRG: T2DM</a>
                    <a href="nephrology_study_guide1.html#ckd" class="guide-link">Nephro: CKD</a>
                </div>
            </div>
        </div>

        <!-- EMPAGLIFLOZIN -->
        <div class="drug-card" data-search="empagliflozin jardiance sglt2 inhibitor heart failure ckd dka euglycemic fournier">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Empagliflozin</span>
                <span class="drug-brand">(Jardiance)</span>
                <span class="drug-class-badge">SGLT2 Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits SGLT2 in proximal tubule ‚Üí blocks glucose reabsorption ‚Üí glycosuria. Also causes natriuresis, reduces preload, and has renoprotective effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>T2DM (especially with ASCVD, HF, or CKD)</li>
                            <li><strong>HFrEF and HFpEF</strong> (with or without diabetes - EMPEROR trials)</li>
                            <li><strong>CKD</strong> (slows progression - EMPA-KIDNEY)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>T2DM</td><td>10-25 mg daily</td></tr>
                            <tr><td>HF</td><td>10 mg daily</td></tr>
                            <tr><td>CKD</td><td>10 mg daily (can initiate down to eGFR 20)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Genital mycotic infections</strong> (candidiasis - counsel on hygiene)</li>
                            <li><strong>UTIs</strong></li>
                            <li><strong>Euglycemic DKA</strong> (can occur with normal glucose - hold during illness/surgery)</li>
                            <li>Volume depletion, hypotension</li>
                            <li>Fournier's gangrene (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Euglycemic DKA: Can occur with near-normal glucose. Hold SGLT2i during acute illness, surgery, prolonged fasting, or if DKA suspected.</div>
                <div class="pearl-box">SGLT2 inhibitors reduce HF hospitalizations and slow CKD progression INDEPENDENT of glucose lowering - now guideline-recommended for HF and CKD even without diabetes.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="nephrology_study_guide1.html#ckd" class="guide-link">Nephro: CKD</a>
                </div>
            </div>
        </div>

        <!-- SEMAGLUTIDE -->
        <div class="drug-card" data-search="semaglutide ozempic wegovy rybelsus glp1 agonist weight loss cardiovascular">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Semaglutide</span>
                <span class="drug-brand">(Ozempic, Wegovy, Rybelsus)</span>
                <span class="drug-class-badge">GLP-1 Receptor Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">GLP-1 receptor agonist ‚Üí enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases satiety. Does NOT cause hypoglycemia as monotherapy.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>T2DM (especially with ASCVD or high CV risk)</li>
                            <li><strong>Weight management</strong> (Wegovy - higher doses)</li>
                            <li>CV risk reduction in T2DM (SUSTAIN-6, SELECT)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>Ozempic (SubQ weekly)</td><td>0.25 mg √ó 4 weeks</td><td>0.5-1 mg weekly (max 2 mg)</td></tr>
                            <tr><td>Wegovy (SubQ weekly)</td><td>0.25 mg √ó 4 weeks</td><td>2.4 mg weekly</td></tr>
                            <tr><td>Rybelsus (oral daily)</td><td>3 mg √ó 30 days</td><td>7-14 mg daily</td></tr>
                        </table>
                        <p><strong>Rybelsus:</strong> Take on empty stomach with ‚â§4 oz water, 30 min before food</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Nausea, vomiting, diarrhea (dose-dependent, improves with time)</li>
                            <li>Pancreatitis (rare)</li>
                            <li>Gallbladder disease</li>
                            <li>Injection site reactions</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome (thyroid C-cell tumors in rodents).</div>
                <div class="pearl-box">GLP-1 agonists provide significant weight loss (10-15% with semaglutide) and CV benefit. Now preferred over sulfonylureas and often used early in T2DM.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#t2dm" class="guide-link">IMCRG: T2DM</a>
                    <a href="im_guidev3B20.html#obesity" class="guide-link">IMCRG: Obesity</a>
                </div>
            </div>
        </div>

        <!-- INSULIN GLARGINE -->
        <div class="drug-card" data-search="insulin glargine lantus basaglar basal long-acting hypoglycemia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Insulin Glargine</span>
                <span class="drug-brand">(Lantus, Basaglar, Toujeo)</span>
                <span class="drug-class-badge">Long-Acting Insulin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Long-acting basal insulin analog. Forms microprecipitates after SubQ injection ‚Üí slow, steady release over ~24 hours. Relatively peakless.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>T1DM (basal component of basal-bolus regimen)</li>
                            <li>T2DM (when oral agents insufficient)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>T2DM initiation</td><td>10 units daily OR 0.1-0.2 units/kg daily</td></tr>
                            <tr><td>Titration</td><td>Increase by 2-4 units every 3-7 days to fasting glucose goal</td></tr>
                            <tr><td>T1DM</td><td>~50% of total daily dose as basal</td></tr>
                        </table>
                        <p>Inject at same time daily (bedtime or morning)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypoglycemia</strong> - less nocturnal hypoglycemia than NPH</li>
                            <li>Weight gain</li>
                            <li>Injection site reactions, lipohypertrophy</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Glargine is "peakless" basal insulin - less nocturnal hypoglycemia than NPH. Cannot be mixed with other insulins. Toujeo (U-300) has even flatter profile.</div>
            </div>
        </div>

        <!-- INSULIN LISPRO -->
        <div class="drug-card" data-search="insulin lispro humalog rapid-acting bolus mealtime hypoglycemia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Insulin Lispro</span>
                <span class="drug-brand">(Humalog)</span>
                <span class="drug-class-badge">Rapid-Acting Insulin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Rapid-acting insulin analog. Faster onset and shorter duration than regular insulin - better matches postprandial glucose rise.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Pharmacokinetics</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Parameter</th><th>Lispro</th><th>Regular</th></tr>
                            <tr><td>Onset</td><td>15-30 min</td><td>30-60 min</td></tr>
                            <tr><td>Peak</td><td>0.5-2.5 hr</td><td>2-4 hr</td></tr>
                            <tr><td>Duration</td><td>3-5 hr</td><td>5-8 hr</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Give within 15 min of starting meal</li>
                            <li>Dose based on carbohydrate counting OR fixed doses</li>
                            <li>Correction factor: 1 unit typically lowers glucose 25-50 mg/dL</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Rapid-acting insulins (lispro, aspart, glulisine) are preferred over regular insulin for mealtime dosing - better match to postprandial glucose and less late hypoglycemia.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= GI MEDICATIONS ======================= -->
<div class="drug-category" id="gi-meds">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü´Å GI / Hepatic Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- PANTOPRAZOLE -->
        <div class="drug-card" data-search="pantoprazole protonix ppi proton pump inhibitor gerd ulcer gi bleed">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Pantoprazole</span>
                <span class="drug-brand">(Protonix)</span>
                <span class="drug-class-badge">Proton Pump Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Irreversibly inhibits H+/K+-ATPase (proton pump) in gastric parietal cells ‚Üí blocks final step of acid secretion. Most potent acid suppressants.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GERD</li>
                            <li>Peptic ulcer disease (treatment and prophylaxis)</li>
                            <li>H. pylori eradication (part of triple/quadruple therapy)</li>
                            <li>GI bleed prophylaxis (stress ulcer prophylaxis in ICU)</li>
                            <li>Zollinger-Ellison syndrome</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>GERD</td><td>40 mg PO daily √ó 4-8 weeks</td></tr>
                            <tr><td>GI bleed (acute)</td><td>80 mg IV bolus, then 8 mg/hr infusion √ó 72h</td></tr>
                            <tr><td>Stress ulcer prophylaxis</td><td>40 mg IV/PO daily</td></tr>
                        </table>
                        <p>Take 30-60 min before meals for best efficacy</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects (Long-term)</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>C. difficile infection</strong> (reduced gastric acid barrier)</li>
                            <li><strong>Hypomagnesemia</strong> (check Mg if prolonged use)</li>
                            <li>Vitamin B12 deficiency</li>
                            <li>Increased fracture risk</li>
                            <li>Possible increased pneumonia risk</li>
                            <li>AIN (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Avoid long-term PPI use without clear indication - reassess periodically. Associated with C. diff, hypomagnesemia, B12 deficiency, fractures.</div>
                <div class="pearl-box">For GI bleed: High-dose PPI (80 mg bolus + 8 mg/hr drip) is used post-endoscopy for high-risk ulcers. Intermittent dosing may be equivalent to continuous.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#gi-bleed" class="guide-link">IMCRG: GI Bleed</a>
                    <a href="id_guide5_5_integrated.html#cdiff" class="guide-link">ID Guide: C. diff</a>
                </div>
            </div>
        </div>

        <!-- LACTULOSE -->
        <div class="drug-card" data-search="lactulose hepatic encephalopathy ammonia cirrhosis laxative constipation">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Lactulose</span>
                <span class="drug-brand">(Enulose, Kristalose)</span>
                <span class="drug-class-badge">Osmotic Laxative</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-absorbable disaccharide ‚Üí metabolized by colonic bacteria to organic acids ‚Üí lowers colonic pH ‚Üí traps ammonia as NH4+ (non-absorbable) ‚Üí excretion. Also osmotic laxative effect.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hepatic encephalopathy</strong> (first-line treatment and prophylaxis)</li>
                            <li>Chronic constipation</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>HE (acute)</td><td>30-45 mL (20-30 g) PO q1h until bowel movement, then TID-QID</td></tr>
                            <tr><td>HE (maintenance)</td><td>30-45 mL BID-TID; titrate to 2-3 soft stools/day</td></tr>
                            <tr><td>HE (severe/comatose)</td><td>300 mL in 700 mL water/NS as retention enema q4-6h</td></tr>
                            <tr><td>Constipation</td><td>15-30 mL daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Bloating, flatulence, abdominal cramps</li>
                            <li>Diarrhea (dose-related)</li>
                            <li>Electrolyte disturbances with excessive diarrhea</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Titrate lactulose to 2-3 soft bowel movements per day. Rifaximin can be added for refractory/recurrent HE (reduces ammonia-producing bacteria).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hepatic-encephalopathy" class="guide-link">IMCRG: Hepatic Encephalopathy</a>
                    <a href="im_guidev3B20.html#cirrhosis" class="guide-link">IMCRG: Cirrhosis</a>
                </div>
            </div>
        </div>

        <!-- RIFAXIMIN -->
        <div class="drug-card" data-search="rifaximin xifaxan hepatic encephalopathy ibs-d travelers diarrhea sibo">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Rifaximin</span>
                <span class="drug-brand">(Xifaxan)</span>
                <span class="drug-class-badge">Non-Absorbable Antibiotic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Rifamycin derivative - inhibits bacterial RNA synthesis. Minimal systemic absorption (<0.4%) ‚Üí acts locally in GI tract.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hepatic encephalopathy (add to lactulose for recurrent episodes)</li>
                            <li>IBS-D (diarrhea-predominant)</li>
                            <li>Traveler's diarrhea (E. coli)</li>
                            <li>SIBO (off-label)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>HE prevention</td><td>550 mg PO BID (long-term)</td></tr>
                            <tr><td>IBS-D</td><td>550 mg TID √ó 14 days (can repeat)</td></tr>
                            <tr><td>Traveler's diarrhea</td><td>200 mg TID √ó 3 days</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Rifaximin reduces recurrent HE by ~50% when added to lactulose. Very expensive but effective - reserve for recurrent HE after lactulose optimization.</div>
            </div>
        </div>

        <!-- OCTREOTIDE -->
        <div class="drug-card" data-search="octreotide sandostatin somatostatin variceal bleeding carcinoid acromegaly">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Octreotide</span>
                <span class="drug-brand">(Sandostatin)</span>
                <span class="drug-class-badge">Somatostatin Analog</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Synthetic somatostatin analog ‚Üí inhibits splanchnic vasodilation, reduces portal pressure, decreases GI hormone secretion (glucagon, insulin, GH, VIP).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Variceal bleeding</strong> (acute management)</li>
                            <li>Carcinoid syndrome (flushing, diarrhea)</li>
                            <li>Acromegaly</li>
                            <li>Secretory diarrhea (VIPoma, short bowel)</li>
                            <li>Sulfonylurea overdose (refractory hypoglycemia)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Variceal bleed</td><td>50 mcg IV bolus, then 50 mcg/hr infusion √ó 3-5 days</td></tr>
                            <tr><td>Carcinoid crisis prevention</td><td>250-500 mcg IV before procedures</td></tr>
                            <tr><td>SU overdose</td><td>50-100 mcg SubQ q6-12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">For variceal bleeding: Start octreotide immediately (don't wait for endoscopy) + antibiotics + PPI. Continue for 3-5 days.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#gi-bleed" class="guide-link">IMCRG: GI Bleed</a>
                    <a href="im_guidev3B20.html#cirrhosis" class="guide-link">IMCRG: Cirrhosis</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= IMMUNOSUPPRESSANTS ======================= -->
<div class="drug-category" id="immunosuppressants">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üõ°Ô∏è Immunosuppressants</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- TACROLIMUS -->
        <div class="drug-card" data-search="tacrolimus prograf calcineurin inhibitor transplant nephrotoxic tremor hyperglycemia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Tacrolimus</span>
                <span class="drug-brand">(Prograf)</span>
                <span class="drug-class-badge">Calcineurin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds FKBP12 ‚Üí inhibits calcineurin ‚Üí blocks IL-2 transcription ‚Üí suppresses T-cell activation. 10-100√ó more potent than cyclosporine.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Solid organ transplant</strong> (kidney, liver, heart - mainstay)</li>
                            <li>Refractory autoimmune diseases</li>
                            <li>Atopic dermatitis (topical)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing & Monitoring</div>
                    <div class="drug-section-content">
                        <p><strong>Initial:</strong> 0.1-0.2 mg/kg/day PO divided BID</p>
                        <p><strong>Trough target:</strong> Varies by transplant type and time post-transplant</p>
                        <ul>
                            <li>Early post-transplant: 10-15 ng/mL</li>
                            <li>Maintenance: 5-10 ng/mL</li>
                        </ul>
                        <p>Check trough level prior to AM dose</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Nephrotoxicity</strong> (dose-dependent, monitor Cr)</li>
                            <li><strong>Neurotoxicity:</strong> Tremor, headache, seizures, PRES</li>
                            <li><strong>Metabolic:</strong> Hyperglycemia/new-onset diabetes, hyperkalemia</li>
                            <li>Hypertension</li>
                            <li>Increased infection risk</li>
                            <li>Hypomagnesemia</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Many drug interactions via CYP3A4. Increase tacrolimus levels: azoles, diltiazem, grapefruit. Decrease: rifampin, phenytoin, St. John's wort.</div>
                <div class="pearl-box">Tacrolimus causes more diabetes/neurotoxicity than cyclosporine but less hirsutism/gingival hyperplasia. Now preferred over cyclosporine in most transplants.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#transplant" class="guide-link">Nephro: Transplant</a>
                </div>
            </div>
        </div>

        <!-- MYCOPHENOLATE -->
        <div class="drug-card" data-search="mycophenolate cellcept myfortic mofetil transplant gi side effects teratogenic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Mycophenolate</span>
                <span class="drug-brand">(CellCept, Myfortic)</span>
                <span class="drug-class-badge">Antimetabolite</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits inosine monophosphate dehydrogenase (IMPDH) ‚Üí blocks de novo purine synthesis ‚Üí selectively inhibits lymphocyte proliferation (lymphocytes lack salvage pathway).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Solid organ transplant (with calcineurin inhibitor + steroids)</li>
                            <li>Lupus nephritis</li>
                            <li>Vasculitis (maintenance)</li>
                            <li>Myasthenia gravis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Dose</th></tr>
                            <tr><td>CellCept (MMF)</td><td>1000-1500 mg PO BID</td></tr>
                            <tr><td>Myfortic (EC-MPA)</td><td>720 mg PO BID (equivalent to CellCept 1000 mg BID)</td></tr>
                        </table>
                        <p>Myfortic is enteric-coated (theoretically less GI side effects)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Diarrhea, nausea, vomiting (most common, dose-limiting)</li>
                            <li><strong>Myelosuppression:</strong> Leukopenia, anemia, thrombocytopenia</li>
                            <li>Increased infection risk (CMV, BK virus)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Teratogenic - pregnancy category D. Effective contraception required. Associated with first-trimester pregnancy loss and congenital malformations.</div>
                <div class="pearl-box">Mycophenolate replaced azathioprine in most transplant protocols - more effective and better tolerated (no hepatotoxicity like azathioprine).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                    <a href="rheumatology_study_guide4.html#sle" class="guide-link">Rheum: SLE</a>
                </div>
            </div>
        </div>

        <!-- AZATHIOPRINE -->
        <div class="drug-card" data-search="azathioprine imuran purine antimetabolite ibd autoimmune tpmt myelosuppression">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Azathioprine</span>
                <span class="drug-brand">(Imuran)</span>
                <span class="drug-class-badge">Purine Antimetabolite</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Prodrug ‚Üí converted to 6-mercaptopurine ‚Üí inhibits purine synthesis ‚Üí suppresses lymphocyte proliferation. Metabolized by TPMT and xanthine oxidase.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>IBD (maintenance)</li>
                            <li>Autoimmune hepatitis</li>
                            <li>Myasthenia gravis</li>
                            <li>SLE, vasculitis (steroid-sparing)</li>
                            <li>Transplant (less common now)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Standard:</strong> 1-3 mg/kg/day PO (typically 50-150 mg daily)</p>
                        <p><strong>Check TPMT genotype/phenotype before starting</strong></p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Interactions</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myelosuppression</strong> (especially with TPMT deficiency)</li>
                            <li>Hepatotoxicity</li>
                            <li>Pancreatitis</li>
                            <li>GI upset</li>
                            <li>Increased malignancy risk (lymphoma, skin cancer)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">ALLOPURINOL INTERACTION: Allopurinol inhibits xanthine oxidase ‚Üí dramatically increases azathioprine levels ‚Üí severe myelosuppression. Reduce azathioprine dose by 75% or avoid.</div>
                <div class="warning-box">Check TPMT before starting. TPMT deficiency ‚Üí severe myelosuppression. Heterozygotes may need dose reduction.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html" class="guide-link">Rheum Guide</a>
                    <a href="im_guidev3B20.html#ibd" class="guide-link">IMCRG: IBD</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= DMARDs & BIOLOGICS ======================= -->
<div class="drug-category" id="dmards-biologics">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä DMARDs & Biologics</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- METHOTREXATE -->
        <div class="drug-card" data-search="methotrexate mtx rheumatrex folate antagonist rheumatoid arthritis psoriasis hepatotoxicity pneumonitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Methotrexate</span>
                <span class="drug-brand">(Rheumatrex, Trexall)</span>
                <span class="drug-class-badge">DMARD / Folate Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits dihydrofolate reductase ‚Üí blocks folate metabolism. At low doses: anti-inflammatory via adenosine release. At high doses: cytotoxic (oncology).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Rheumatoid arthritis</strong> (first-line DMARD)</li>
                            <li>Psoriasis, psoriatic arthritis</li>
                            <li>Ectopic pregnancy</li>
                            <li>Various malignancies (high-dose)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>RA</td><td>7.5-25 mg PO/SubQ ONCE WEEKLY</td></tr>
                            <tr><td>Psoriasis</td><td>10-25 mg PO ONCE WEEKLY</td></tr>
                        </table>
                        <p><strong>ALWAYS give with folic acid 1 mg daily</strong> to reduce toxicity</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>CBC (myelosuppression)</li>
                            <li>LFTs (hepatotoxicity)</li>
                            <li>Creatinine (renally cleared)</li>
                            <li>Baseline CXR (pneumonitis)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Nausea, stomatitis (reduced by folic acid)</li>
                            <li><strong>Hepatotoxicity:</strong> Transaminitis, fibrosis (monitor LFTs)</li>
                            <li><strong>Pulmonary:</strong> Methotrexate pneumonitis (hypersensitivity, any time)</li>
                            <li><strong>Myelosuppression</strong></li>
                            <li>Infection risk</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Teratogenic - avoid in pregnancy (category X). Requires reliable contraception. Wait 3 months after stopping before conception.</div>
                <div class="warning-box">WEEKLY dosing - daily dosing is a fatal medication error. Always verify "weekly" when prescribing.</div>
                <div class="pearl-box">Methotrexate is anchor drug for RA - start early. Combines well with biologics. Low-dose MTX has excellent long-term safety record.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#ra" class="guide-link">Rheum: RA</a>
                </div>
            </div>
        </div>

        <!-- RITUXIMAB -->
        <div class="drug-card" data-search="rituximab rituxan anti-cd20 b cell depletion lymphoma ra vasculitis infusion reaction">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Rituximab</span>
                <span class="drug-brand">(Rituxan)</span>
                <span class="drug-class-badge">Anti-CD20 Monoclonal Ab</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Chimeric anti-CD20 monoclonal antibody ‚Üí B-cell depletion via ADCC, CDC, and apoptosis. CD20 on pre-B cells to mature B cells (not plasma cells).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Non-Hodgkin lymphoma, CLL</li>
                            <li>Rheumatoid arthritis (with MTX, after TNF failure)</li>
                            <li>ANCA-associated vasculitis (GPA, MPA)</li>
                            <li>Membranous nephropathy</li>
                            <li>TTP, ITP</li>
                            <li>Pemphigus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>RA</td><td>1000 mg IV √ó 2 doses (days 1 and 15), repeat q6 months</td></tr>
                            <tr><td>Vasculitis (induction)</td><td>375 mg/m¬≤ weekly √ó 4</td></tr>
                            <tr><td>Lymphoma</td><td>375 mg/m¬≤ weekly √ó 4-8 (varies by protocol)</td></tr>
                        </table>
                        <p>Premedicate: acetaminophen, diphenhydramine, ¬± methylprednisolone</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Infusion reactions</strong> (fever, chills, rigors) - most common with first infusion</li>
                            <li><strong>Infections</strong> (including reactivation of HBV, JC virus ‚Üí PML)</li>
                            <li>Hypogammaglobulinemia (with repeated courses)</li>
                            <li>Late-onset neutropenia</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Screen for Hepatitis B before starting - risk of fatal HBV reactivation. Monitor and consider prophylaxis if HBcAb+.</div>
                <div class="warning-box">PML (progressive multifocal leukoencephalopathy) - rare but serious. Consider in patients with new neurologic symptoms.</div>
                <div class="pearl-box">B-cell depletion lasts 6-12 months. Check CD19/CD20 counts to guide retreatment. May cause prolonged hypogammaglobulinemia with repeated dosing.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#ra" class="guide-link">Rheum: RA</a>
                    <a href="rheumatology_study_guide4.html#vasculitis" class="guide-link">Rheum: Vasculitis</a>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                </div>
            </div>
        </div>

        <!-- ADALIMUMAB -->
        <div class="drug-card" data-search="adalimumab humira tnf inhibitor anti-tnf ra psoriasis ibd infection tb">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Adalimumab</span>
                <span class="drug-brand">(Humira)</span>
                <span class="drug-class-badge">TNF-Œ± Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Fully human monoclonal antibody against TNF-Œ± ‚Üí neutralizes TNF-mediated inflammation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Rheumatoid arthritis</li>
                            <li>Psoriatic arthritis, plaque psoriasis</li>
                            <li>Ankylosing spondylitis</li>
                            <li>Crohn's disease, ulcerative colitis</li>
                            <li>Hidradenitis suppurativa</li>
                            <li>Uveitis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>RA/PsA/AS:</strong> 40 mg SubQ every 2 weeks</p>
                        <p><strong>Crohn's:</strong> 160 mg week 0, 80 mg week 2, then 40 mg q2 weeks</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Serious infections</strong> (including TB, fungal infections)</li>
                            <li>Injection site reactions</li>
                            <li>Demyelinating disease (MS-like)</li>
                            <li>Drug-induced lupus</li>
                            <li>Worsening heart failure</li>
                            <li>Malignancy (lymphoma - rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Screen for latent TB before starting - reactivation risk. Also screen for Hepatitis B. Avoid in active infections and moderate-severe heart failure.</div>
                <div class="pearl-box">All TNF inhibitors require TB screening before initiation. Live vaccines contraindicated during therapy.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#ra" class="guide-link">Rheum: RA</a>
                    <a href="im_guidev3B20.html#ibd" class="guide-link">IMCRG: IBD</a>
                </div>
            </div>
        </div>

        <!-- HYDROXYCHLOROQUINE -->
        <div class="drug-card" data-search="hydroxychloroquine plaquenil antimalarial sle ra retinal toxicity qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Hydroxychloroquine</span>
                <span class="drug-brand">(Plaquenil)</span>
                <span class="drug-class-badge">DMARD / Antimalarial</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Accumulates in lysosomes ‚Üí raises pH ‚Üí interferes with antigen processing and TLR signaling. Anti-inflammatory without significant immunosuppression.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>SLE</strong> (virtually all patients - reduces flares, improves survival)</li>
                            <li>Rheumatoid arthritis (mild disease or combination)</li>
                            <li>Sj√∂gren syndrome</li>
                            <li>Malaria prophylaxis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>SLE/RA:</strong> 200-400 mg PO daily (max 5 mg/kg/day to reduce retinal toxicity)</p>
                        <p>Takes 3-6 months for full effect</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Retinal toxicity</strong> ("bull's eye maculopathy") - irreversible; screen annually after 5 years</li>
                            <li>QTc prolongation</li>
                            <li>GI upset, skin hyperpigmentation</li>
                            <li>Neuromyopathy (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Ophthalmologic exam (OCT, visual fields) at baseline and annually after 5 years of use. Retinal toxicity risk increases with cumulative dose.</div>
                <div class="pearl-box">HCQ is the only DMARD safe in pregnancy - continue in pregnant SLE patients (reduces flares). Also protective against thrombosis in APS.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#sle" class="guide-link">Rheum: SLE</a>
                    <a href="rheumatology_study_guide4.html#ra" class="guide-link">Rheum: RA</a>
                </div>
            </div>
        </div>

        <!-- COLCHICINE -->
        <div class="drug-card" data-search="colchicine colcrys gout pericarditis fmf diarrhea microtubule">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Colchicine</span>
                <span class="drug-brand">(Colcrys)</span>
                <span class="drug-class-badge">Anti-inflammatory</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds tubulin ‚Üí inhibits microtubule assembly ‚Üí blocks neutrophil migration, phagocytosis, and inflammasome activation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Acute gout</li>
                            <li>Gout prophylaxis (when starting ULT)</li>
                            <li><strong>Pericarditis</strong> (reduces recurrence)</li>
                            <li>FMF (familial Mediterranean fever)</li>
                            <li>Beh√ßet disease</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Acute gout (within 36h)</td><td>1.2 mg, then 0.6 mg 1 hour later (total 1.8 mg)</td></tr>
                            <tr><td>Gout prophylaxis</td><td>0.6 mg daily or BID</td></tr>
                            <tr><td>Pericarditis</td><td>0.5 mg BID √ó 3 months</td></tr>
                        </table>
                        <p>Reduce dose with renal impairment and CYP3A4/P-gp inhibitors</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Diarrhea, nausea, vomiting (dose-limiting)</li>
                            <li>Myelosuppression (with overdose or drug interactions)</li>
                            <li>Myopathy, neuropathy (rare, with renal impairment)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">DANGEROUS interactions with strong CYP3A4 inhibitors (clarithromycin, ketoconazole) or P-gp inhibitors (cyclosporine) - can cause fatal toxicity. Reduce dose or avoid.</div>
                <div class="pearl-box">For acute gout: Low-dose colchicine (AGREE trial regimen) is as effective and much better tolerated than old high-dose regimens.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#gout" class="guide-link">Rheum: Gout</a>
                    <a href="im_guidev3B20.html#pericarditis" class="guide-link">IMCRG: Pericarditis</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= PAIN & SEDATION ======================= -->
<div class="drug-category" id="pain-sedation">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Pain & Sedation</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- MORPHINE -->
        <div class="drug-card" data-search="morphine opioid pain mu receptor respiratory depression naloxone">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Morphine</span>
                <span class="drug-brand">(MS Contin, Roxanol)</span>
                <span class="drug-class-badge">Opioid Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œº-opioid receptor agonist ‚Üí analgesia, euphoria, respiratory depression, miosis, decreased GI motility. Also histamine release.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Opioid-Naive Dose</th></tr>
                            <tr><td>IV</td><td>2-4 mg q2-4h PRN</td></tr>
                            <tr><td>PO (IR)</td><td>15-30 mg q4h PRN</td></tr>
                            <tr><td>PO (ER)</td><td>15 mg q12h (titrate)</td></tr>
                        </table>
                        <p><strong>IV:PO ratio = 1:3</strong> (10 mg IV = 30 mg PO)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Respiratory depression</strong> (dose-limiting)</li>
                            <li>Constipation (does NOT develop tolerance)</li>
                            <li>Nausea/vomiting, sedation, pruritus</li>
                            <li>Hypotension (histamine release)</li>
                            <li>Urinary retention</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Active metabolite (M6G) accumulates in renal failure ‚Üí prolonged effect, toxicity. Avoid or reduce dose significantly with CKD. Consider alternatives (fentanyl, hydromorphone).</div>
                <div class="pearl-box">Morphine causes more histamine release (hypotension, pruritus) than other opioids. For hemodynamically unstable patients, fentanyl preferred.</div>
            </div>
        </div>

        <!-- FENTANYL -->
        <div class="drug-card" data-search="fentanyl sublimaze opioid pain icu sedation patch transdermal">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Fentanyl</span>
                <span class="drug-brand">(Sublimaze, Duragesic)</span>
                <span class="drug-class-badge">Opioid Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>50-100√ó more potent than morphine</li>
                            <li>Rapid onset (seconds IV, minutes transdermal)</li>
                            <li>Short duration (IV), prolonged (patch)</li>
                            <li>No active metabolites - safer in renal failure</li>
                            <li>Minimal histamine release - preferred in unstable patients</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>IV (analgesia)</td><td>25-100 mcg q1-2h PRN</td></tr>
                            <tr><td>IV infusion (ICU)</td><td>25-100 mcg/hr</td></tr>
                            <tr><td>Transdermal patch</td><td>12-100 mcg/hr (change q72h)</td></tr>
                        </table>
                        <p><strong>Conversion:</strong> 100 mcg IV fentanyl ‚âà 10 mg IV morphine</p>
                    </div>
                </div>
                <div class="warning-box">Transdermal patch: For opioid-TOLERANT patients only. 12-24h to reach steady state; effects persist 12-24h after removal. Never apply heat (increases absorption).</div>
                <div class="pearl-box">Fentanyl is preferred in renal failure (no active metabolites) and hemodynamic instability (no histamine release). Chest wall rigidity with rapid high-dose IV push.</div>
            </div>
        </div>

        <!-- NALOXONE -->
        <div class="drug-card" data-search="naloxone narcan opioid reversal overdose respiratory depression">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Naloxone</span>
                <span class="drug-brand">(Narcan)</span>
                <span class="drug-class-badge">Opioid Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Competitive Œº-opioid receptor antagonist ‚Üí rapidly reverses opioid effects (respiratory depression, sedation, analgesia).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>Opioid overdose</td><td>0.4-2 mg IV/IM/SubQ/IN, repeat q2-3min PRN</td></tr>
                            <tr><td>Opioid-induced respiratory depression (known tolerance)</td><td>0.04-0.1 mg IV, titrate to respirations (avoid withdrawal)</td></tr>
                            <tr><td>Intranasal (Narcan)</td><td>4 mg IN, may repeat</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Important Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Short duration:</strong> 30-90 min (shorter than most opioids) - may need repeat doses or infusion</li>
                            <li><strong>Precipitates withdrawal</strong> in opioid-dependent patients (not dangerous, but distressing)</li>
                            <li>Goal: Restore respirations, NOT consciousness</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Naloxone duration (30-90 min) is SHORTER than most opioids. Monitor for resedation and redose PRN. Consider infusion (2/3 of effective bolus per hour).</div>
                <div class="pearl-box">In opioid-tolerant patients, titrate small doses (0.04-0.1 mg) to avoid precipitating severe withdrawal. Goal is adequate ventilation, not full alertness.</div>
            </div>
        </div>

        <!-- PROPOFOL -->
        <div class="drug-card" data-search="propofol diprivan sedation icu anesthesia hypotension propofol infusion syndrome">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Propofol</span>
                <span class="drug-brand">(Diprivan)</span>
                <span class="drug-class-badge">IV Anesthetic/Sedative</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Potentiates GABA-A receptor ‚Üí CNS depression. Rapid onset and offset. Lipid emulsion formulation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>ICU sedation (mechanically ventilated)</li>
                            <li>Procedural sedation</li>
                            <li>General anesthesia induction/maintenance</li>
                            <li>Refractory status epilepticus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Induction</td><td>1-2.5 mg/kg IV push</td></tr>
                            <tr><td>ICU sedation</td><td>5-50 mcg/kg/min (titrate to goal RASS)</td></tr>
                            <tr><td>Procedural sedation</td><td>0.5-1 mg/kg, then 25-75 mcg/kg/min</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypotension</strong> (common - bolus fluid, consider vasopressors)</li>
                            <li><strong>Respiratory depression/apnea</strong></li>
                            <li>Injection site pain</li>
                            <li>Hypertriglyceridemia (lipid emulsion - check TG if prolonged use)</li>
                            <li><strong>Propofol infusion syndrome</strong> (PRIS) - rare, fatal</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Propofol Infusion Syndrome (PRIS): High doses (>83 mcg/kg/min) for >48h ‚Üí metabolic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure. Monitor for early signs.</div>
                <div class="pearl-box">Propofol has NO analgesic effect - always combine with opioid for painful procedures/conditions. Lipid emulsion provides 1.1 kcal/mL - count toward nutrition.</div>
            </div>
        </div>

        <!-- KETAMINE -->
        <div class="drug-card" data-search="ketamine ketalar dissociative nmda anesthesia analgesia bronchospasm">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ketamine</span>
                <span class="drug-brand">(Ketalar)</span>
                <span class="drug-class-badge">Dissociative Anesthetic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">NMDA receptor antagonist ‚Üí dissociative anesthesia, analgesia, amnesia. Maintains airway reflexes and respiratory drive. Sympathomimetic (releases catecholamines).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Procedural sedation</li>
                            <li>RSI induction (hemodynamically unstable, bronchospasm)</li>
                            <li>Analgesia (low-dose)</li>
                            <li>Treatment-resistant depression (esketamine)</li>
                            <li>Status asthmaticus (bronchodilation)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Procedural sedation</td><td>1-2 mg/kg IV or 4-5 mg/kg IM</td></tr>
                            <tr><td>RSI induction</td><td>1-2 mg/kg IV</td></tr>
                            <tr><td>Analgesia (low-dose)</td><td>0.1-0.3 mg/kg IV</td></tr>
                            <tr><td>Infusion (analgesia)</td><td>0.1-0.5 mg/kg/hr</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Emergence phenomena (hallucinations, dysphoria) - reduced with benzodiazepines</li>
                            <li>Hypersalivation (consider glycopyrrolate)</li>
                            <li>Hypertension, tachycardia (sympathomimetic)</li>
                            <li>Increased ICP (controversial)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Ketamine is ideal for bronchospasm (bronchodilator) and hypotensive patients (maintains BP). Maintains airway reflexes - but not a substitute for NPO status.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTICONVULSANTS ======================= -->
<div class="drug-category" id="anticonvulsants">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üß† Anticonvulsants</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- LEVETIRACETAM -->
        <div class="drug-card" data-search="levetiracetam keppra seizure epilepsy behavioral irritability">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Levetiracetam</span>
                <span class="drug-brand">(Keppra)</span>
                <span class="drug-class-badge">Anticonvulsant</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds SV2A (synaptic vesicle protein) ‚Üí modulates neurotransmitter release. Exact mechanism not fully understood.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Focal (partial) seizures</li>
                            <li>Generalized tonic-clonic seizures</li>
                            <li>Myoclonic seizures</li>
                            <li>Status epilepticus (second-line)</li>
                            <li>Seizure prophylaxis (TBI, SAH, post-craniotomy)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Maintenance</td><td>500-1500 mg PO/IV BID (max 3000 mg/day)</td></tr>
                            <tr><td>Status epilepticus</td><td>20-60 mg/kg IV (max 4500 mg)</td></tr>
                        </table>
                        <p><strong>Renal dosing:</strong> Reduce dose with CrCl &lt;80</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Behavioral:</strong> Irritability, aggression ("Keppra rage"), depression</li>
                            <li>Sedation, fatigue</li>
                            <li>Minimal drug interactions (not CYP450 metabolized)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Levetiracetam advantages: No drug interactions, IV=PO dosing, no drug level monitoring needed. Disadvantage: Behavioral side effects. Can give vitamin B6 to reduce irritability.</div>
            </div>
        </div>

        <!-- PHENYTOIN -->
        <div class="drug-card" data-search="phenytoin dilantin fosphenytoin seizure status epilepticus purple glove zero order">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Phenytoin/Fosphenytoin</span>
                <span class="drug-brand">(Dilantin / Cerebyx)</span>
                <span class="drug-class-badge">Na+ Channel Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Blocks voltage-gated sodium channels ‚Üí stabilizes neuronal membranes, reduces seizure spread.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>Loading (SE)</td><td>20 mg PE/kg IV (fosphenytoin) at 150 mg PE/min</td></tr>
                            <tr><td>Maintenance</td><td>100 mg PO/IV TID or 300 mg daily (extended)</td></tr>
                        </table>
                        <p><strong>Fosphenytoin:</strong> Dosed in phenytoin equivalents (PE). Faster infusion, less tissue necrosis.</p>
                        <p><strong>Target level:</strong> 10-20 mcg/mL (total) or 1-2 mcg/mL (free)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Pharmacokinetics</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Zero-order kinetics:</strong> Small dose changes ‚Üí large level changes</li>
                            <li>90% protein-bound - check FREE level in renal failure, hypoalbuminemia</li>
                            <li>CYP450 inducer - many drug interactions</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Acute toxicity:</strong> Nystagmus ‚Üí ataxia ‚Üí lethargy ‚Üí coma (dose-related)</li>
                            <li><strong>Chronic:</strong> Gingival hyperplasia, hirsutism, coarsening of features</li>
                            <li>Purple glove syndrome (IV phenytoin extravasation)</li>
                            <li>Hypotension, bradycardia (rapid infusion)</li>
                            <li>SJS/TEN (HLA-B*15:02 in Asian patients)</li>
                            <li>Osteoporosis (vitamin D metabolism)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">IV phenytoin: Max rate 50 mg/min (cardiac toxicity). Use fosphenytoin when possible - faster infusion, less tissue injury. Check free level in renal failure/low albumin.</div>
                <div class="pearl-box">Corrected phenytoin (Sheiner-Tozer): For albumin <3.5, adjusted level = measured/(0.2 √ó albumin + 0.1). Or just check free level directly.</div>
            </div>
        </div>

        <!-- VALPROIC ACID -->
        <div class="drug-card" data-search="valproic acid depakote valproate seizure bipolar migraine hepatotoxicity pancreatitis teratogenic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Valproic Acid</span>
                <span class="drug-brand">(Depakote, Depakene)</span>
                <span class="drug-class-badge">Anticonvulsant / Mood Stabilizer</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Multiple mechanisms: Increases GABA, blocks sodium channels, modulates T-type calcium channels.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Generalized seizures (absence, myoclonic, tonic-clonic)</li>
                            <li>Focal seizures</li>
                            <li>Status epilepticus</li>
                            <li>Bipolar disorder (mania)</li>
                            <li>Migraine prophylaxis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Seizures</td><td>10-15 mg/kg/day, increase to 20-60 mg/kg/day</td></tr>
                            <tr><td>Status epilepticus</td><td>20-40 mg/kg IV load</td></tr>
                            <tr><td>Migraine prophylaxis</td><td>500-1000 mg/day divided</td></tr>
                        </table>
                        <p><strong>Target level:</strong> 50-100 mcg/mL</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset, weight gain, hair loss</li>
                            <li>Tremor</li>
                            <li><strong>Hepatotoxicity</strong> (especially children <2, polypharmacy)</li>
                            <li><strong>Pancreatitis</strong></li>
                            <li>Thrombocytopenia, platelet dysfunction</li>
                            <li>Hyperammonemia (even with normal LFTs)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Highly teratogenic - neural tube defects. Contraindicated in pregnancy for migraine/bipolar. If must use for epilepsy, use lowest effective dose + high-dose folate.</div>
                <div class="warning-box">Valproate + carbapenem (meropenem, ertapenem) ‚Üí dramatically reduces VPA levels. Avoid combination or use alternative antibiotic.</div>
                <div class="pearl-box">Check ammonia if altered mental status on valproate - hyperammonemic encephalopathy can occur even with therapeutic levels and normal LFTs. Treat with lactulose or L-carnitine.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= TOXICOLOGY & ANTIDOTES ======================= -->
<div class="drug-category" id="toxicology">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ò†Ô∏è Toxicology & Antidotes</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- N-ACETYLCYSTEINE -->
        <div class="drug-card" data-search="n-acetylcysteine nac acetaminophen tylenol overdose glutathione rumack matthew">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">N-Acetylcysteine (NAC)</span>
                <span class="drug-brand">(Mucomyst, Acetadote)</span>
                <span class="drug-class-badge">Acetaminophen Antidote</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Replenishes glutathione stores ‚Üí detoxifies NAPQI (toxic acetaminophen metabolite). Also direct hepatoprotective effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Acetaminophen overdose</strong> (most effective within 8-10h, beneficial up to 24h+)</li>
                            <li>Acetaminophen level above Rumack-Matthew nomogram line</li>
                            <li>Acute liver failure (any etiology - some benefit)</li>
                            <li>Contrast-induced nephropathy prevention (controversial)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Protocol</th></tr>
                            <tr><td>IV (21-hour)</td><td>150 mg/kg over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h</td></tr>
                            <tr><td>PO (72-hour)</td><td>140 mg/kg load, then 70 mg/kg q4h √ó 17 doses</td></tr>
                        </table>
                        <p>IV and PO equally effective. IV preferred if vomiting or altered mental status.</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Anaphylactoid reaction</strong> (flushing, bronchospasm, hypotension) - usually with IV loading; slow infusion, give antihistamines</li>
                            <li>Nausea, vomiting (PO - smells like sulfur)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Start NAC if ANY concern for significant ingestion - don't wait for level if >8 hours post-ingestion. NAC is virtually non-toxic and can be stopped if not indicated.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#acetaminophen" class="guide-link">IMCRG: Acetaminophen OD</a>
                </div>
            </div>
        </div>

        <!-- FLUMAZENIL -->
        <div class="drug-card" data-search="flumazenil romazicon benzodiazepine reversal overdose seizure">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Flumazenil</span>
                <span class="drug-brand">(Romazicon)</span>
                <span class="drug-class-badge">Benzodiazepine Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Competitive antagonist at GABA-A benzodiazepine binding site ‚Üí reverses benzodiazepine effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Procedural sedation reversal:</strong> 0.2 mg IV over 15 sec, repeat 0.2 mg q1min PRN (max 1 mg)</p>
                        <p><strong>Overdose:</strong> 0.2 mg IV, then 0.3 mg, then 0.5 mg q1min (max 3-5 mg)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è CRITICAL Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Chronic benzodiazepine use</strong> - precipitates withdrawal seizures</li>
                            <li><strong>Seizure disorder</strong> controlled by benzodiazepines</li>
                            <li><strong>Mixed overdose</strong> with pro-convulsant (TCA, cocaine)</li>
                            <li>Unknown ingestion history</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Can precipitate seizures in benzodiazepine-dependent patients or mixed overdoses. Rarely indicated in overdose setting - supportive care preferred. Reserved for iatrogenic oversedation.</div>
                <div class="warning-box">Duration shorter than most benzodiazepines - resedation may occur. Monitor for at least 2 hours after last dose.</div>
            </div>
        </div>

        <!-- FOMEPIZOLE -->
        <div class="drug-card" data-search="fomepizole antizol methanol ethylene glycol toxic alcohol alcohol dehydrogenase">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Fomepizole</span>
                <span class="drug-brand">(Antizol)</span>
                <span class="drug-class-badge">Alcohol Dehydrogenase Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits alcohol dehydrogenase ‚Üí blocks conversion of methanol/ethylene glycol to toxic metabolites (formic acid, glycolic acid/oxalate).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Methanol poisoning</strong></li>
                            <li><strong>Ethylene glycol poisoning</strong></li>
                            <li>Suspected toxic alcohol with metabolic acidosis + osmol gap</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Loading:</strong> 15 mg/kg IV over 30 min</p>
                        <p><strong>Maintenance:</strong> 10 mg/kg q12h √ó 4 doses, then 15 mg/kg q12h until level <20</p>
                        <p><strong>During dialysis:</strong> q4h dosing (drug removed by HD)</p>
                    </div>
                </div>
                <div class="pearl-box">Fomepizole is preferred over ethanol infusion - easier to dose, no CNS depression. Start empirically if toxic alcohol suspected while awaiting levels. Dialysis indicated for severe acidosis, renal failure, visual symptoms (methanol), or high levels.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#toxic-alcohol" class="guide-link">IMCRG: Toxic Alcohols</a>
                    <a href="nephrology_study_guide1.html#acidosis" class="guide-link">Nephro: Metabolic Acidosis</a>
                </div>
            </div>
        </div>

        <!-- ACTIVATED CHARCOAL -->
        <div class="drug-card" data-search="activated charcoal decontamination ingestion overdose aspiration">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Activated Charcoal</span>
                <span class="drug-brand">(Actidose)</span>
                <span class="drug-class-badge">GI Decontaminant</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Highly porous surface adsorbs toxins in GI tract ‚Üí prevents systemic absorption.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ When to Use</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Within 1-2 hours of ingestion (greatest benefit)</li>
                            <li>Potentially life-threatening ingestion</li>
                            <li>Airway protected (alert or intubated)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Single dose:</strong> 1 g/kg PO/NG (typical adult dose 50-100g)</p>
                        <p><strong>Multi-dose:</strong> 25-50g q4-6h (for carbamazepine, dapsone, phenobarbital, quinine, theophylline)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Contraindications & Limitations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Not adsorbed:</strong> Metals (iron, lithium, lead), alcohols, hydrocarbons, acids/alkalis</li>
                            <li><strong>Contraindicated:</strong> Unprotected airway, GI perforation/obstruction, caustic ingestion</li>
                            <li>Risk of aspiration pneumonitis</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Remember "PHAILS" - charcoal does NOT adsorb: Pesticides/petroleum, Hydrocarbons, Acids/alkalis/alcohols, Iron, Lithium, Solvents.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ELECTROLYTE REPLACEMENT ======================= -->
<div class="drug-category" id="electrolytes">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚öóÔ∏è Electrolyte Replacement</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- POTASSIUM -->
        <div class="drug-card" data-search="potassium kcl hypokalemia replacement iv oral">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Potassium Chloride</span>
                <span class="drug-brand">(KCl, K-Dur)</span>
                <span class="drug-class-badge">Electrolyte</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Replacement Guidelines</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>K+ Level</th><th>Replacement</th></tr>
                            <tr><td>3.0-3.4 mEq/L</td><td>40-80 mEq PO daily</td></tr>
                            <tr><td>2.5-2.9 mEq/L</td><td>40 mEq PO q4-6h OR 10-20 mEq/hr IV</td></tr>
                            <tr><td>&lt;2.5 or symptomatic</td><td>10-20 mEq/hr IV (max 40 mEq/hr via central line)</td></tr>
                        </table>
                        <p><strong>Rule of thumb:</strong> 10 mEq K+ raises serum K+ by ~0.1 mEq/L</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Safety</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Max peripheral IV rate:</strong> 10 mEq/hr (burning, phlebitis)</li>
                            <li><strong>Max central IV rate:</strong> 20-40 mEq/hr with cardiac monitoring</li>
                            <li>Always check Mg (hypomagnesemia ‚Üí refractory hypokalemia)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Can't correct hypokalemia without correcting hypomagnesemia - Mg is required for K+ retention. Always check and replace Mg first.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#hypokalemia" class="guide-link">Nephro: Hypokalemia</a>
                </div>
            </div>
        </div>

        <!-- MAGNESIUM -->
        <div class="drug-card" data-search="magnesium sulfate oxide hypomagnesemia torsades eclampsia asthma">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Magnesium</span>
                <span class="drug-brand">(MgSO4, Mg Oxide)</span>
                <span class="drug-class-badge">Electrolyte</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypomagnesemia</li>
                            <li><strong>Torsades de pointes</strong> (even with normal Mg)</li>
                            <li><strong>Eclampsia/preeclampsia</strong> prophylaxis</li>
                            <li>Severe asthma (bronchodilation)</li>
                            <li>Digoxin toxicity with arrhythmia</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Mild deficiency</td><td>1-2 g IV over 1h or PO</td></tr>
                            <tr><td>Moderate deficiency</td><td>2-4 g IV over 4-6h</td></tr>
                            <tr><td>Torsades (acute)</td><td>2 g IV push over 1-2 min</td></tr>
                            <tr><td>Eclampsia prophylaxis</td><td>4-6 g IV load, then 1-2 g/hr</td></tr>
                            <tr><td>Severe asthma</td><td>2 g IV over 20 min</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Flushing, hypotension (rapid infusion)</li>
                            <li>Muscle weakness, hyporeflexia (toxicity)</li>
                            <li>Respiratory depression (severe toxicity)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Monitor reflexes (first sign of toxicity). Antidote for Mg toxicity: Calcium gluconate 1-2 g IV. Reduce dose in renal failure.</div>
                <div class="pearl-box">1 g MgSO4 = 8 mEq Mg = 98 mg elemental Mg. Serum Mg poorly reflects total body stores - may need empiric replacement.</div>
            </div>
        </div>

        <!-- CALCIUM -->
        <div class="drug-card" data-search="calcium gluconate chloride hypocalcemia hyperkalemia ccb overdose">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Calcium Gluconate/Chloride</span>
                <span class="drug-brand">(CaCl, Ca Gluconate)</span>
                <span class="drug-class-badge">Electrolyte</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Symptomatic hypocalcemia (tetany, seizures, QT prolongation)</li>
                            <li><strong>Hyperkalemia</strong> with EKG changes (cardiac membrane stabilization)</li>
                            <li>Calcium channel blocker overdose</li>
                            <li>Hydrofluoric acid burns</li>
                            <li>Magnesium toxicity</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Elemental Ca</th><th>Dose</th></tr>
                            <tr><td>Ca Gluconate 10%</td><td>93 mg per 10 mL</td><td>1-2 g (10-20 mL) IV over 10 min</td></tr>
                            <tr><td>Ca Chloride 10%</td><td>273 mg per 10 mL</td><td>500 mg-1 g (5-10 mL) IV over 5 min</td></tr>
                        </table>
                        <p><strong>Ca Gluconate:</strong> Preferred for peripheral IV (less tissue necrosis)</p>
                        <p><strong>Ca Chloride:</strong> 3√ó more elemental Ca, central line preferred</p>
                    </div>
                </div>
                <div class="warning-box">Ca Chloride causes severe tissue necrosis with extravasation - use central line or Ca Gluconate peripherally. Do NOT mix with bicarbonate (precipitates).</div>
                <div class="pearl-box">Calcium in hyperkalemia: Stabilizes cardiac membrane but does NOT lower K+. Effect lasts 30-60 min - use as bridge while other treatments take effect.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                    <a href="nephrology_study_guide1.html#hypocalcemia" class="guide-link">Nephro: Hypocalcemia</a>
                </div>
            </div>
        </div>

        <!-- SODIUM BICARBONATE -->
        <div class="drug-card" data-search="sodium bicarbonate nahco3 metabolic acidosis hyperkalemia tca overdose urine alkalinization">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sodium Bicarbonate</span>
                <span class="drug-brand">(NaHCO3)</span>
                <span class="drug-class-badge">Alkalinizing Agent</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Severe metabolic acidosis (pH <7.1, controversial)</li>
                            <li><strong>Hyperkalemia</strong> (shifts K+ into cells, especially with acidosis)</li>
                            <li><strong>TCA overdose</strong> (treats sodium channel blockade - wide QRS)</li>
                            <li>Salicylate toxicity (urine alkalinization)</li>
                            <li>Rhabdomyolysis prevention (urine pH >6.5)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Severe acidosis</td><td>1-2 mEq/kg IV bolus</td></tr>
                            <tr><td>Hyperkalemia</td><td>50-100 mEq IV over 5 min</td></tr>
                            <tr><td>TCA toxicity</td><td>1-2 mEq/kg IV bolus, repeat PRN for QRS narrowing</td></tr>
                            <tr><td>Urine alkalinization</td><td>150 mEq in 1L D5W at 150-200 mL/hr</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Causes CO2 generation (paradoxical intracellular acidosis)</li>
                            <li>Volume overload, hypernatremia</li>
                            <li>Hypokalemia (K+ shifts into cells)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">TCA overdose: Bicarb boluses to achieve arterial pH 7.50-7.55 and narrow QRS <100 ms. Much more effective than lidocaine for TCA-induced arrhythmias.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#acidosis" class="guide-link">Nephro: Metabolic Acidosis</a>
                    <a href="im_guidev3B20.html#hyperkalemia" class="guide-link">IMCRG: Hyperkalemia</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- FOOTER AND JAVASCRIPT -->
<div class="footer">
    <p><strong>Comprehensive Drug Reference Guide</strong></p>
    <p>Extracted from: Internal Medicine CRG, Nephrology, Rheumatology, and Infectious Disease Study Guides</p>
    <p>Version 1.0 | Created December 2024 | For educational purposes</p>
    <a href="#toc" class="back-to-top">‚Üë Back to Top</a>
</div>

</div><!-- end container -->

<script>
// Toggle category expand/collapse
function toggleCategory(header) {
    const content = header.nextElementSibling;
    header.classList.toggle('collapsed');
    content.classList.toggle('collapsed');
}

// Toggle individual drug card
function toggleDrug(header) {
    const body = header.nextElementSibling;
    const toggle = header.querySelector('.drug-toggle');
    body.classList.toggle('expanded');
    toggle.textContent = body.classList.contains('expanded') ? '‚ñº' : '‚ñ∂';
}

// Search functionality
document.addEventListener('DOMContentLoaded', function() {
    const searchInput = document.getElementById('drugSearch');
    const searchClear = document.getElementById('searchClear');
    const searchResults = document.getElementById('searchResults');
    const drugCards = document.querySelectorAll('.drug-card');
    const categories = document.querySelectorAll('.drug-category');
    
    searchInput.addEventListener('input', function() {
        const query = this.value.toLowerCase().trim();
        let visibleCount = 0;
        
        if (query === '') {
            // Show all
            drugCards.forEach(card => {
                card.classList.remove('hidden');
            });
            categories.forEach(cat => {
                cat.style.display = 'block';
            });
            searchClear.style.display = 'none';
            searchResults.textContent = '';
            return;
        }
        
        searchClear.style.display = 'flex';
        
        // Filter drugs
        drugCards.forEach(card => {
            const searchData = card.getAttribute('data-search') || '';
            const drugName = card.querySelector('.drug-name')?.textContent || '';
            const drugBrand = card.querySelector('.drug-brand')?.textContent || '';
            const fullText = (searchData + ' ' + drugName + ' ' + drugBrand).toLowerCase();
            
            if (fullText.includes(query)) {
                card.classList.remove('hidden');
                visibleCount++;
            } else {
                card.classList.add('hidden');
            }
        });
        
        // Hide categories with no visible drugs
        categories.forEach(cat => {
            const visibleDrugs = cat.querySelectorAll('.drug-card:not(.hidden)');
            if (visibleDrugs.length === 0) {
                cat.style.display = 'none';
            } else {
                cat.style.display = 'block';
                // Expand category if collapsed
                const header = cat.querySelector('.category-header');
                const content = cat.querySelector('.category-content');
                if (content.classList.contains('collapsed')) {
                    header.classList.remove('collapsed');
                    content.classList.remove('collapsed');
                }
            }
        });
        
        searchResults.textContent = `Found ${visibleCount} medications`;
    });
    
    searchClear.addEventListener('click', function() {
        searchInput.value = '';
        searchInput.dispatchEvent(new Event('input'));
        searchInput.focus();
    });
});
</script>

</body>
</html>
